Assessing Nurses\u27 Demographic Cardiovascular Risk Factors and Pharmacogenetic Testing Knowledge and Acceptance by Ohanuka, Stella Chibuzor
Walden University
ScholarWorks
Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral StudiesCollection
2017
Assessing Nurses' Demographic Cardiovascular
Risk Factors and Pharmacogenetic Testing
Knowledge and Acceptance
Stella Chibuzor Ohanuka
Walden University
Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Public Health Education and Promotion Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been
accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please
contact ScholarWorks@waldenu.edu.
 Walden University 
 
 
 
College of Health Sciences 
 
 
 
 
This is to certify that the doctoral dissertation by 
 
 
Stella Ohanuka 
 
 
has been found to be complete and satisfactory in all respects,  
and that any and all revisions required by  
the review committee have been made. 
 
 
Review Committee 
Dr. Richard Palmer, Committee Chairperson, Public Health Faculty 
Dr. Harold Griffin, Committee Member, Public Health Faculty 
Dr. Simone Salandy, University Reviewer, Public Health Faculty 
 
 
 
 
 
Chief Academic Officer 
Eric Riedel, Ph.D. 
 
 
 
Walden University 
2017 
 
 
  
                                                             Abstract 
Assessing Nurses’ Demographic Cardiovascular Risk Factors and 
Pharmacogenetic Testing Knowledge and Acceptance 
By 
Stella Chibuzor Ohanuka 
MSN Gardner-Webb University, 2007 
BSN, University of South Carolina, 1996 
Proposal Submitted in Partial Fulfillment 
Of the Requirements for the Degree of 
Doctor of Philosophy 
Public Health Epidemiology 
Walden University  
February 2017 
 Abstract 
The lack of knowledge of pharmacogenetic testing for cardiovascular disease (CVD), 
coupled with their increased risk for CVD, may impair nurses’ cognitions and attitudes 
toward pharmacogenetic testing for CVD. The purpose of this quantitative cross-sectional 
correlational study, conducted with 230 RNs without CVD who worked in acute-care 
settings in Georgia, was to determine if their years of education, years of experience, and 
gender significantly influenced their perceived risk for CVD (Questions 1–3) and their 
perceived knowledge of pharmacogenetic testing for CVD (Questions 4–6), and if their 
perceived risk for CVD significantly influenced their acceptance of pharmacogenetic 
testing for CVD (Question 7). Various regression analyses (hierarchical multiple linear 
regression, multiple linear regression, hierarchical, linear regression) were conducted for 
hypothesis testing. Results showed that: (a) gender significantly predicted perceived risk 
for CVD, in that male nurses perceived themselves to be more at risk for CVD than did 
female nurses; (b) years of education was a significant predictor of knowledge of 
pharmacogenetic testing for CVD, in that as nurses’ education level increased, so did 
their knowledge; and (c) knowledge of pharmacogenetic testing for CVD, but not 
perceived risk for CVD, significantly predicted acceptance of pharmacogenetic testing 
for CVD. This study may act as a catalyst to promote empirical work and inform practice 
in nurses’ CVD health and their knowledge and acceptance of pharmacogenetic testing 
for CVD. 
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Chapter 1: Introduction 
Cardiovascular diseases (CVDs) are disorders that affect the heart, such as 
hypertension with or without renal disease, stroke, atherosclerosis, rheumatic fever, 
coronary heart disease, and heart failure (American Heart Association [AHA], 2015; 
Centers for Disease Control and Prevention [CDC], 2015). As of 2014, approximately 82 
million adults in the United States had some form of heart disease (AHA, 2015; CDC, 
2015). Moreover, one in every three individuals in the United States had at least one risk 
factor for CVD (Go et al., 2013). Cardiovascular disease is the leading cause of death 
among U.S. adults (AHA, 2015). 
Nurses are knowledgeable about CVD (Paul & Hice, 2014), yet studies have 
documented that they are at risk for CVD (Lang, Lepage, Schieber, Lamy, & Kelly-
Irving, 2012; McElligott, Siemers, Thomas, & Kohn, 2009). Obesity, diabetes, and high 
cholesterol are significantly associated with increased risk of mortality due to CVD 
(AHA, 2015). In comparison to the 35.7% of American adults who are obese, 57% to 
70% of nurses are obese (American Nurses Association [ANA], 2015). Across studies 
examining CVD risk factors in nurses, results have shown that the average percentage of 
nurses with diabetes is 10%, higher than the 8.3% of Americans in general with diabetes 
(ANA, 2015). The percentage of nurses with elevated cholesterol levels has ranged from 
15% to 50% across studies (Khan et al., 2012; Lang et al., 2012; Puett et al., 2009), 
substantially higher than the 12.9% of American adults with high cholesterol (Cho & Lee, 
2012). Sedentary behavior, poor dietary behaviors, and smoking additionally place nurses 
at risk for CVD (Khan et al., 2012; Louie & Wedell, 2014). In a study conducted by the 
Preventive Cardiovascular Nurses Association (2008), 43% of nurses did not engage in 
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regular physical activity, 50% had very poor diets, and 18% of surveyed nurses were 
smokers. Moreover, Lang et al. (2012) found that the rate CVD was elevated in nurses 
due to the high rates of work-related stress and negative social interactions between 
nurses and their supervisors. 
The elevated risk for CVD among nurses is further complicated by their perceived 
lack of risk for developing CVD (Hörnsten, Lindahl, Persson, & Edvardsson, 2014; Jones, 
Weaver, Grimley, Appel, & Ard, 2006). Results from the few studies that have examined 
perceived risk for CVD among nurses have shown that, despite having numerous risk 
factors for CVD, nurses do not believe they are especially at risk for CVD (Hörnsten et 
al., 2014; Jones et al., 2006). If nurses perceive their risk for developing CVD is low, 
they may lack motivation to change behaviors that place them at increased risk for CVD 
(Khan et al., 2012). 
Advances in genetics, medicine, and healthcare technology have brought CVD 
genomic medicine models to the patient-centered healthcare system (Humma & Terra, 
2012; Johnson & Cavallari, 2013; Kee, Hayes, & McCuistion, 2014). Among the newest 
of genomic medical approaches for CVD management is pharmacogenetic testing 
(Howland, 2012; Johnson & Cavallari, 2013; Musunuru et al., 2012). Pharmacogenetic 
testing, which is a form of genetic testing, refers to the process of identifying and 
considering differences in an individual’s genetic makeup, so that practitioners can 
attempt to anticipate a client’s reaction to medications and make appropriate prescriptive 
decisions (Blakey & Hall, 2011; Howland, 2012; Musunuru et al., 2012; Shin, Kayer, & 
Langaee, 2009). 
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Acute-care nurses must have knowledge of the most current healthcare practices 
and the ability to effectively transfer this knowledge to the patient-provider domain 
(Chadwell, 2013; McNeils, Ironside, Zvonar, & Ebright, 2014). Acute-care nurses work 
in a hospital setting with patients experiencing short-term acute medical problems; they 
differ from critical-care nurses, who work in intensive-care units and emergency 
medicine (Rosenthal & Guerrasio, 2009). In the future, acute-care nurses may be 
expected to provide patient education related to pharmacogenetic testing (Johnson & 
Cavallari, 2013).The knowledge base of nurses (and other healthcare providers) of 
pharmacogenetic testing is limited as a result of the newness of such testing and the 
existing controversy that surrounds it such as confidentiality of test results (Johnson & 
Cavallari, 2013; Verschuren et al., 2011). Knowledge and acceptance of pharmacogenetic 
testing related to CVD is also relevant in the field of nursing due to the high prevalence 
rate of CVD in nurses (Lang et al., 2012; McElligott et al., 2009). 
Results from this study have the potential to effect positive social change on 
numerous levels and impact many stakeholders. For example, student nurses working in a 
healthcare setting were increasingly focused on genomic medicine models, requiring they 
have current relevant knowledge and skills to provide effective and meaningful patient 
care (Maughan, Bobo, Butler, Schantz, & Schoessler, 2015). Results can inform changes 
in nursing education, especially in the development of courses and curricula focusing on 
genetics and pharmacogenetic testing. Health-promotion interventions for nurses have 
become increasingly important with the national shortage of nurses, as participation in 
such programs can reduce work-related stress and absenteeism (Kaewthummanukul & 
Brown, 2006; Nahm, Warren, Zhu, An, & Brown, 2012). Due to their low perceived risk 
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of CVD, despite having numerous risk factors for CVD, coupled with their lack of 
knowledge and acceptance of CVD-related medical practices including pharmacogenetic 
testing for CVD, acute-care nurses may not be good patient advocates and role models in 
CVD risk prevention and reduction (Nahm et al., 2012). Results from the present study 
can increase understanding of the demographic and work factors related to perceived risk 
for CVD among nurses, which can result in targeted interventions specific to nurses’ 
gender, education level, and years of practice. Moreover, this study’s findings can 
empower nurses to become social-change agents by adopting patient-centered practices 
aimed at reducing CVD risk and increasing patient knowledge and understanding of 
pharmacogenetic testing. 
The purpose of this chapter is to introduce and elaborate on the proposed study 
and to provide specific information on the study’s purpose and methodology. The chapter 
opens with a background section that reviews the pertinent literature on study topics, 
which then informs the statement of the problem. The chapter includes a summary of the 
purpose of the study and the research questions and hypotheses. The chapter elucidates 
the guiding theory of the study, followed by a section on the nature of the study. The 
chapter then continues with sections on definitions, assumptions, scope and delimitations, 
limitations, and significance. A summary concludes the chapter. 
Background 
Pharmacogenetic testing has been recognized in the medical community as a 
means to prevent and treat CVD, and tests are currently added to a host of diagnostic 
measures to identify the risks associated with CVD and to manage the disease in those 
patients with CVD (Dodson, 2011; Roederer, Van Riper, Valgus, Knafl, & McLeod, 
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2012; Squassina et al., 2010). Pharmacogenetic testing, which is a form of genetic testing, 
refers to the process of identifying and considering differences in an individual’s genetic 
makeup, so practitioners can attempt to anticipate a client’s reaction to medications and 
make appropriate prescriptive decisions (Blakey & Hall, 2011; Howland, 2012). 
Although pharmacogenetic testing in the clinical arena is relatively new, the use of such 
testing is slowly gaining momentum (Kee et al., 2014). 
Nurses in general and acute-care nurses specifically must have a strong 
knowledge base regarding CVD (Johnson & Cavallari, 2013). However, researchers have 
shown that acute-care nurses may have limited knowledge of CVD-related issues, 
including heart-failure principles, asymptomatic hypotension, advanced risk assessment 
of CVD, clinical best practices for CVD, and pharmacogenetic testing for CVD (Calzone, 
Jenkins, Culp, Bonham, & Badzek, 2013; Delaney, Apostolidis, Lachapelle, & Fortinsky, 
2011; Lanuza, Davidson, Dunbar, Hughes, & De Geest, 2011). 
Researchers have also shown that nurses have numerous risk factors for CVD 
(Lang et al., 2012; Louie & Wedell, 2014; McElligott et al., 2009; Slater, McElwee, 
Fleming, & McKenna, 2005). According to a study by Louie and Wedell (2014), who 
used data from the Nurses’ Health Study (NHS), 60% of acute-care nurses who 
participated in the study were obese or overweight and more than 50% of participants 
were severely inactive and had poor dietary habits. In another survey conducted by the 
Preventive Cardiovascular Nurses Association (2008), 47% of acute-care nurses were 
overweight/obese, 43% did not engage in physical activity, 50% had very poor diets, and 
18% were smokers. 
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Moreover, the few studies addressing CVD in nurses documented a “paradox” 
between actual risk and perceived risk for CVD among nurses: they do not perceive 
themselves as being at risk for CVD despite having numerous risk factors for this disease 
(Hörnsten et al., 2014; Jones et al., 2006). This lack of congruence may not only impair 
the health and work behaviors of nurses, but may also influence their cognitions and 
attitudes toward CVD-related practices, such as pharmacogenetic testing for CVD (Chan 
& Perry, 2012; Jones et al., 2006). Acute-care nurses may not be good role models for 
CVD risk reduction or promotion of emerging treatments for CVD, including 
pharmacogenetic testing (Louie & Wedell, 2014). 
The U.S. healthcare system has become a patient-centered medical community 
that is quickly moving toward a genomic model of health practice, requiring that nurses 
have specific knowledge and skills with regard to CVD, genetics, and pharmacogenetic 
testing to be effective healthcare providers (Kee et al., 2014). Nurses must have the most 
current knowledge of CVD, increasingly need to have knowledge of pharmacogenetic 
testing for CVD, must be able to advocate for such testing, and should be able to translate 
the meaning of such testing to their patients (Kee et al., 2014). It remains unclear, 
however, as to whether demographic factors such as gender, years of education, and years 
of practice play a role in influencing nurses’ knowledge of their perceived risk for CVD 
as well as pharmacogenetic testing for CVD, and if their knowledge of pharmacogenetics 
for CVD influences their acceptance of its use. 
Problem Statement 
Nurses are known to have numerous risk factors for CVD that may not only 
impair their health and work behaviors, but may also influence their work-related 
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attitudes and behaviors toward CVD-related practices, such as pharmacogenetic testing 
for CVD (Dodson, 2011, 2014; Knisely, Carpenter, & Von Ah, 2014; J. Zhang, While, & 
Norman, 2010). The incidence of CVD can be reduced through preventive measures such 
as health-promotion programs, and nurses are the ones assessing risk factors and 
promoting lifestyle changes for their patients (Fair, Gulanick, & Braun, 2009). Teaching 
patients and their families how to achieve CVD health (e.g., healthy eating habits, 
smoking cessation, blood-pressure screening, cholesterol screening, and active lifestyle, 
to mention but a few) is a core competency of the nursing profession (ANA, 2015; Kee et 
al., 2014). 
Genetic tests are currently added to a host of diagnostic measures to identify the 
risks associated with CVD and to manage the disease in those patients with CVD (ANA, 
2015; Heller, Fisher, Marks, & Hsieh, 2014). Pharmacogenetic testing, which is a form of 
genetic testing, refers to the process of identifying and considering differences in an 
individual’s genetic makeup, so practitioners can attempt to anticipate a client’s reaction 
to medications and make appropriate prescriptive decisions (Heller et al., 2014).  
Although pharmacogenetic testing in the clinical arena is relatively new, the use 
of such testing is slowly gaining momentum (Heller et al., 2014). Studies conducted 
during the emergence of genomic medicine in the mid- to late 2000s (Elder, 2007; Haga 
& Burke, 2008; Shin et al., 2009) reported that acceptance by healthcare professionals—
especially nurses—was the most influential factor in whether patients accepted and used 
a new test. Results from contemporary research (e.g., Cuffe et al., 2014; Hess, Fonseca, 
Scott, & Fagerness, 2015) continue to support this argument. 
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Studies conducted with groups of healthcare professionals that have included 
nurses (e.g., Dodson, 2011; Dodson & Van Riper, 2011; Moen & Lamba, 2012) and were 
made up solely of nurses (e.g., Kadafour, Haugh, Posin, Kayser, & Shin, 2009; Van Riper, 
Barksdale, & Knafl, 2011), have documented that nurses have limited knowledge of 
pharmacogenetic testing. Dodson’s (2011) review of the literature on healthcare 
providers’ knowledge of pharmacogenetic testing showed that the majority (66% to 84%) 
of healthcare providers, including nurses, reported minimal knowledge of 
pharmacogenetic testing. In Moen and Lamba’s (2012) study, conducted with healthcare 
professionals including nurses, 4% of respondents believed they were well educated 
about the subject. In the same study, healthcare professionals who were 30 years or 
younger and worked less than 4 years had a higher level of familiarization with 
pharmacogenetics (Moen & Lamba, 2012). 
Although the percentage of nurses who reported poor understanding of 
pharmacogenetic testing was lower in studies conducted by Van Riper et al. (2011) and 
Kadafour et al. (2009)—33% and 40% respectively—these percentages are 
disconcertingly high. Although it is clear that some disparities exist in what healthcare 
professionals know and how they feel about pharmacogenetic testing, currently not as 
well-understood are factors that may explain some of those differences in knowledge 
(Dodson, 2011; Howland, 2012). As stated by Dodson (2011), “since nursing is a key 
link between physicians and patients, more research needs to be done to assess nursing 
knowledge and attitudes towards pharmacogenetic testing” (p. 427). 
Gaps in knowledge persist in nurses’ perceptions of their risk for CVD and their 
knowledge of pharmacogenetic testing for CVD (Kee et al., 2014). As stated previously, 
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studies have shown that a paradox exists between actual risks and perceived risk for CVD 
among nurses in that they do not perceive themselves to be a risk for CVD (Hörnsten et 
al., 2014; Jones et al., 2006). Healthcare leaders lack understanding, however, of whether 
demographic factors such as gender, years of education, and years of nursing experience 
may influence this perceived risk. It is important to gain clarity on these associations, 
especially as these predictors tie to CVD risk (Berry et al., 2012; Go et al., 2013; Lang et 
al., 2012). 
It is also important to assess if gender, years of education, and years of nursing 
experience play a role in the level of pharmacogenetic testing for CVD. For example, yet 
another paradox exists that increased years of nursing experience aligns with lowered 
degrees of knowledge of pharmacogenetic testing for CVD. Understanding the linkages 
between gender, years of education, and years of nursing experience and 
pharmacogenetic testing for CVD is highly pertinent to the existing literature on nurses’ 
ethical concerns and perceived advantages of pharmacogenetic testing (Calzone et al., 
2010; Dodson, 2011; Dodson & Van Riper, 2011). Linkages between nurses’ knowledge 
and attitudes toward pharmacogenetic testing for CVD are missing in the empirical 
literature. These associations also relate to ethical concerns on the part of the nurse as 
well as the practitioners who develop interventions for nurses to best address these 
knowledge gaps. 
Purpose of the Study 
The purpose of this quantitative study, using a cross-sectional design, was to 
determine if acute care nurses’ gender, highest level of education, and years of nursing 
experience significantly influenced their perceived risk for CVD and their knowledge of 
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pharmacogenetic testing for CVD, and whether significant associations exist between 
nurses’ perceived risk for CVD and their acceptance of pharmacogenetic testing for CVD. 
This study had seven research questions. The first set of three questions (Questions 1–3) 
determined if the independent variables of acute-care nurses’ years of education, years of 
experience, and gender significantly influenced their perceived risk for CVD, the 
dependent variable. The second set of three questions (Questions 4–6) assessed if the 
independent variables of acute-care nurses’ years of education, years of experience, and 
gender significantly influenced their perceived knowledge of pharmacogenetic testing for 
CVD, the dependent variable. The seventh and last research question examined if acute-
care nurses’ perceived risk for CVD, the independent variable, significantly influenced 
their acceptance of pharmacogenetic testing for CVD, the dependent variable. I included 
two potential covariates, health factors related to estrogen and medication-related CVD 
risk, in the study as potential covariates. I conducted this study with a sample of 228 
registered acute-care nurses who reside and work in acute-care hospital settings in 
Atlanta, Georgia. As the study examined risk factors for CVD, the sample included only 
acute-care nurses who have not been diagnosed with CVD. 
Research Questions and Hypotheses 
I conducted this quantitative study using a cross-sectional research design with 
licensed acute-care nurses who work in Atlanta, Georgia. I posited seven questions with 
associated null and alternative hypotheses for this study. 
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Research Question 1 
Is there a significant association between acute-care nurses’ years of education 
and perceived risk for CVD, controlling for health factors related to estrogen and 
medication-related CVD risk? 
H01. There is no association between acute-care nurses’ years of education and 
perceived risk for CVD, controlling for health factors related to estrogen and 
medication-related CVD risk. 
Ha1. There is a significant association between acute-care nurses’ years of 
education and perceived risk for CVD, controlling for health factors related to 
estrogen and medication-related CVD risk. 
Research Question 2 
Is there a significant association between acute-care nurses’ years of practice and 
perceived risk for CVD, controlling for health factors related to estrogen and medication-
related CVD risk? 
Ho2. There is no association between acute-care nurses’ years of practice and 
perceived risk for CVD, controlling for health factors related to estrogen and 
medication-related CVD risk. 
Ha2 There is a significant association between acute-care nurses’ years of practice 
and perceived risk for CVD, controlling for health factors related to estrogen 
and medication-related CVD risk. 
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Research Question 3 
Is there a significant association between acute-care nurses’ gender and perceived 
risk for CVD, controlling for health factors related to estrogen and medication-related 
CVD risk? 
Ho3. There is no association between acute-care nurses’ gender and perceived 
risk for CVD, controlling for health factors related to estrogen and 
medication-related CVD risk. 
Ha3. There is a significant association between acute-care nurses’ gender and 
perceived risk for CVD, controlling for health factors related to estrogen and 
medication-related CVD risk. 
Research Question 4 
Is there a significant association between acute-care nurses’ years of education 
and knowledge of pharmacogenetic testing for CVD, controlling for health factors related 
to estrogen and medication-related CVD risk? 
Ho4. There is no association between acute-care nurses’ years of education and 
knowledge of pharmacogenetic testing for CVD, controlling for health factors 
related to estrogen and medication-related CVD risk. 
Ha4. There is a significant association between acute-care nurses’ years of 
education and knowledge of pharmacogenetic testing for CVD, controlling for 
health factors related to estrogen and medication-related CVD risk. 
Research Question 5 
Is there a significant association between acute-care nurses’ years of practice and 
knowledge of pharmacogenetic testing for CVD, controlling for health factors related to 
13 
 
estrogen and medication-related CVD risk, controlling for health factors related to 
estrogen and medication-related CVD risk? 
Ho5. There is no association between acute-care nurses’ years of practice and 
knowledge of pharmacogenetic testing for CVD, controlling for health factors 
related to estrogen and medication-related CVD risk. 
Ha5. There is a significant association between acute-care nurses’ years of 
practice and knowledge of pharmacogenetic testing for CVD, controlling for 
health factors related to estrogen and medication-related CVD risk. 
Research Question 6 
Is there a significant association between acute-care nurses’ gender and 
knowledge of pharmacogenetic testing for CVD, controlling for health factors related to 
estrogen and medication-related CVD risk? 
Ho6. There is no association between acute-care nurses’ gender and knowledge of 
pharmacogenetic testing for CVD, controlling for health factors related to 
estrogen and medication-related CVD risk. 
Ha6. There is a significant association between acute-care nurses’ gender and 
knowledge of pharmacogenetic testing for CVD, controlling for health factors 
related to estrogen and medication-related CVD risk. 
Research Question 7 
Is there a significant association between acute-care nurses’ perceived risk for 
CVD and acceptance of pharmacogenetic testing for CVD, controlling for health factors 
related to estrogen and medication-related CVD risk? 
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Ho7. There is no association between acute-care nurses’ perceived risk for CVD 
and acceptance of pharmacogenetic testing for CVD, controlling for health 
factors related to estrogen and medication-related CVD risk. 
Ha7. There is a significant association between acute-care nurses’ perceived risk 
for CVD and acceptance of pharmacogenetic testing for CVD, controlling for 
health factors related to estrogen and medication-related CVD risk. 
Theoretical Framework 
The health belief model (HBM), developed by Rosenstock and colleagues (i.e., 
Becker & Rosenstock, 1987; Hochbaum, Rosenstock, & Kegels, 1952; Rosenstock, 1974; 
Rosenstock, Strecher, & Becker, 1988), was the guiding theory for this study. The HBM 
posits that engaging in a preventative health behavior—the likelihood of action—depends 
on the individual’s perceptions of a disease (i.e., the perceived seriousness of it coupled 
with the perceived likelihood of acquiring it) and their perceptions of a new health 
behavior (i.e., the benefits of engaging in a health behavior and the barriers that could 
prevent the individual from adopting it; Rosenstock, 1974; Rosenstock et al., 1988). 
Perceptions of the disease and the health-behavior change needed to reduce its likelihood 
are influenced by modifying factors (i.e., demographic, psychological, and cognitive 
factors of the individual) and cues to action (i.e., such things as doctors’ reminders and 
advice from others; Rosenstock, 1974; Rosenstock et al., 1988). 
As it is a health change model, it is unsurprising that the HBM has been used in 
numerous nursing studies (e.g., Hong, Kim, & Suh, 2010; Shahrabani, Benzion, & Yom 
Din, 2009; Tastan, Iyigün, Kilic, & Unver, 2011; J. Zhang et al., 2010). Empirical 
researchers have used the HBM to explain nurses’ health behavioral changes in influenza 
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vaccinations (e.g., Shahrabani et al., 2009; J. Zhang et al., 2010), cancer screenings (e.g., 
Tastan et al., 2011; Yaren, Ozklinc, Guler, & Oztop, 2008), physical activity and exercise 
(Kaewthummanukul & Brown, 2006; Nahm et al., 2012), and medical services use (Hong 
et al., 2010).  
What is surprising is the dearth of literature that has used the HBM to explain 
nurses’ health behaviors surrounding CVD and its prevention. A review of the nursing 
literature published between 2000 and 2015 that involved an examination of at least two 
elements of the HBM yielded one quantitative study by Jones et al. (2006). The authors 
focused their study on the influence of modifying factors on perceived susceptibility of 
CVD among 194 African American nurses who did not have CVD (Jones et al., 2006). 
Despite having numerous risk factors for CVD (e.g., being of older age, 
overweight/obese, and sedentary), nurses did not perceive themselves to be at risk for 
developing CVD, even though their knowledge of CVD was quite substantial (Jones et al., 
2006). 
The implications of the Jones et al. (2006) results were quite profound, especially 
when considering the central role of nurses in personalized medicine that increasingly 
uses genomic models (Frazier, Wung, Sparks, & Eastwood, 2009; Howland, 2012). If 
nurses do not perceive themselves to be at risk for developing CVD, despite having risk 
factors for CVD—and knowledge of these risk factors—they may be quick to overlook or 
dismiss CVD risk factors in their patients (Jones et al., 2006). Nurses may also be less 
likely to promote advances in CVD prevention and treatment, such as pharmacogenetic 
testing for CVD, especially if they perceive such advances as relevant only to severe or 
unusual cases of CVD (Dodson, 2011, 2014; Fair, Gulanick, & Braun, 2009; J. Zhang et 
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al., 2010). A review of the literature review from 2000 uncovered no studies that were 
guided by the HBM and involved CVD risk among acute-care nurses. This was a 
disconcerting gap in the literature, yet it validated the need for this study. 
Using the HBM, this study examined if the modifying factors of gender, highest 
level of education, and years of practice significantly influenced a perception of the 
disease outcome (perceived risk for CVD) and a perception of the health change 
behavior outcome (knowledge of pharmacogenetic testing for CVD). The study further 
examined if a perception of the disease outcome (perceived risk for CVD) significantly 
influenced a likelihood of action outcome (acceptance of pharmacogenetic testing for 
CVD). 
Nature of the Study 
I used a quantitative design for this study. The quantitative design was appropriate 
as I used the scientific method; that is, I developed hypotheses that were tested through 
statistical analysis of numerical data (aligned with Stangor, 2014). The study did not use 
an experimental research design as the goal of the study was not to test effects from an 
intervention or to determine differences between groups of acute-care nurses; rather, the 
study provides an examination of relationships between naturally occurring variables (i.e., 
risk factors and knowledge and acceptance of pharmacogenetic testing; Stangor, 2014). 
This study was correlational, as I sought to determine, through statistical analyses, 
theory-driven relationships between the independent variables and the dependent 
variables in an objective manner (as explained by Stangor, 2014). A cross-sectional 
design was appropriate because I measured these variables at a one point in time rather 
than over a period of time (Stangor, 2014). 
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I conducted this quantitative correlational cross-sectional study with a sample of 
228 registered nurses (RNs) without CVD working in acute-care settings in Georgia. This 
study had seven research questions with differing independent and dependent variables. 
For Questions 1–3, I conducted a hierarchical multiple linear regression (HMLR) to 
assess if the independent variables of nurses’ years of education, years of experience, and 
gender significantly predicted the dependent variable of perceived risk for CVD. The 
variable of take medications, which could include blood pressure medications, was 
included in the HMLR analysis as a covariate, as it significantly aligned with the 
dependent variable. For Questions 4–6, I performed a multiple linear regression (MLR) to 
determine if the independent variables of years of education, years of experience, and 
gender significantly predicted the dependent variable of knowledge of pharmacogenetic 
testing for CVD. For the seventh and last research question, I ran a hierarchical linear 
regression (HLR) to ascertain if the independent variable of perceived risk for CVD was 
a significant predictor of acceptance of pharmacogenetic testing for CVD. I included the 
variable of knowledge of pharmacogenetic testing as a covariate in the HLR due to its 
significant association with the dependent variable. 
Definitions of Terms 
Cardiovascular diseases (CVDs). Cardiovascular diseases are diseases that 
involve the human body’s cardiovascular system. The main causes of CVD are blockage 
of the heart and hypertension (Frazier, Johnson, & Sparks, 2009). 
Deoxyribonucleic acid (DNA). DNA refers to the molecule that encodes the 
genetic instructions used for the functioning of all living things and viruses (Haga & 
LaPointe, 2013). 
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Pharmacogenetics. Pharmacogenetics refers to the application of genomic 
technologies to the discovery of new drugs to determine the variability of individual 
genes in susceptibility to disease as well as drug response (Calzone et al, 2010). 
Pharmacotherapy. Pharmacotherapy refers to the use of medication for disease 
management (Calzone et al, 2010). 
Assumptions 
This study rested on certain assumptions or aspects of the research study that I 
accepted as true (aligned with Stangor, 2014). The positivist paradigm that reality is 
objective guides quantitative studies, assuming the researcher is knowledgeable of this 
reality and the researcher can explain this objective reality by the use of the scientific 
method. In accordance with the scientific method, I established a priori hypotheses and, 
through the use of statistical analyses, drew objective conclusions about study findings 
(as suggested by Stangor, 2014). 
Methodological assumptions in this study concerned issues related to study 
participants and instruments. I assumed, as study criteria, that participants were registered 
acute-care nurses in Atlanta who do not have CVD. This study used an online survey 
platform to obtain study data. To increase assurances that this assumption was met, 
participants had to provide correct responses to screening questions before they could 
take the online survey, including questions that they consented to the study, that they 
were registered acute-care nurses with active nursing licenses, and that they did not have 
CVD. A methodological assumption was that participants understood survey questions, 
answered the survey honestly, and provided responses that truly reflected their attitudes, 
beliefs, and knowledge about survey topics (as put forth by Stangor, 2014). 
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Scope and Delimitations 
I considered a few theoretical models prior to selecting Rosenstock’s (1974) 
HBM. Bandura’s (1974) social-cognitive theory was too general and its theoretical 
components (e.g., self-efficacy and modeling) did not capture the constructs examined in 
this study. I also gave attention to Pender’s (1982) health-promotion model (HPM), 
especially as it was developed specific to the nursing field. Key components of the HPM 
(e.g., prior behaviors and social support) were not emphasized in this study model; 
ultimately I decided the study topics did not adequately fit with Pender’s HPM. 
Rosenstock’s (1974) HBM aligned well with the study topics and provided a meaningful 
framework for the relationships between variables in this study. 
The present study was limited to registered licensed acute-care nurses who work 
in hospital acute-care settings in Atlanta without a CVD diagnosis. Data collection 
occurred during the fall of 2015. The decision to limit the study to acute-care nurses 
rested on their routine involvement with patients who have numerous types of CVDs and 
the critical roles they play in CVD patient diagnosis, assessment, treatment, management, 
and education. I excluded nurses who did not work in acute-care settings from this study, 
and nurses who did not have access to a computer or did not have the computer skills to 
be able to link to the survey and complete it. As I provided no translation of the survey, 
nurses had to have the ability to read and write in English. The criteria set for inclusion 
and exclusion may have reduced the generalizability of study results. 
In the present study, pharmacogenetic testing was limited to CVD, as CVD 
among nurses was the focal point of the study. The decision to limit the independent 
variables to gender, level of education, and years of practice for the first six questions 
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rested not only on Rosenstock’s (1974) HBM, but also on prior literature that identified 
gender, level of education, and years of practice as risk factors for CVD in acute-care 
nurses (Tucker, Harris, Pipe, & Stevens, 2010; Zapka, Lemon, Magner, & Hale, 2009) 
and as factors significantly related to knowledge of pharmacogenetic testing among the 
general public (e.g., Haga, O’Daniel, Tindall, Lipkus, & Agans, 2012). I included the 
seventh research question examining the relationship between perceived risk for CVD 
and acceptance of pharmacogenetic testing for CVD to provide a holistic examination of 
pharmacogenetic testing for CVD. 
Limitations 
This study had a few limitations or elements of the study that were beyond the 
control (as explained by Stangor, 2014). Although researcher objectivity is a desired goal 
in any quantitative study, the researcher is human and is not necessarily neutral or value 
free. In parallel, a possibility exists that participants differed in their understanding and 
interpretation of survey questions, which may influence study data. The use of 
convenience sampling in this study was a limitation. Convenience sampling increases the 
likelihood that the participants are not a representative sample of the population of RNs 
working in acute-care settings in Atlanta, Georgia. Another limitation of this study was 
the use of a quantitative nonexperimental design, which precluded the ability to infer 
cause-and-effect (aligned with Stangor, 2014). 
Objectivity is of the utmost importance in empirical research, and a certain degree 
of objectivity is not only necessary but required to reach sound study conclusions 
(Stangor, 2014). However, research conducted with human subjects, especially research 
using nonexperimental methods, has some methodological and design limitations that can 
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reduce study objectivity and quality. Study objectivity can improve as researchers 
establish sound study-validity processes (Jackson, 2015). 
Study Internal Validity 
Internal validity “speaks to the validity of the research itself” (Stangor, 2014, 
p. 34). It pertains to the degree of accuracy of the relationship between the independent 
and dependent variables (Stangor, 2014). Nonexperimental research studies are limited 
by certain issues that reduce the internal validity of a study, otherwise known as threats 
to internal validity (Jackson, 2015). One threat to internal validity, confound bias, has the 
potential to make the study as a whole invalid (Jackson, 2015). Confound bias results in 
the inability to conclude that the dependent variable effects were a result of the 
independent variable or were due to an unmeasured “third variable”—a variable that 
significantly aligns with the independent and the dependent variables (Armistead, 2014, 
p. 2). 
Although researchers cannot completely eliminate the “third variable problem” 
(Armistead, 2014, p. 2), it was reduced in this study by controlling for covariates: 
variables known to relate to the independent and the dependent variable (Jackson, 2015). 
This study had two potential covariates. The first covariate was estrogen-related health 
factors/events (e.g., postmenopausal status, hormone-replacement therapy, or birth 
control pills). The second covariate was medication(s) used for health conditions other 
than CVD but that nonetheless increase CVD risk (e.g., birth control or prednisone) or 
decrease CVD risk (e.g., diuretics). I determined significant associations between the two 
covariates and the three dependent variables by significant (i.e., p < .05) Spearman’s rho 
correlation coefficients (Stangor, 2014), if found to be significantly associated with any 
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of the three dependent variables in this study, I controlled for covariates in the statistical 
analyses for hypothesis testing, HMLR, by entering them in the first step or model of the 
HMLR (Jackson, 2015). 
One other bias common to nonexperimental research studies, especially those 
using self-report instruments, is social desirability bias, where participants provide 
answers to survey questions that are not truthful but present a “favorable image” of the 
participant (Armistead, 2014, p. 5). Social desirability bias increases when researchers 
ask participants sensitive questions (Armistead, 2014). Although this study did not 
include questions that were highly sensitive, participants may have provided answers on 
the perceived risk for CVD scale that were socially desirable in that nurses may have 
thought they should have few or no risk factors for CVD. I reviewed participant data for 
extreme scores and outliers and adjusted accordingly (i.e., winsorized outliers; Armistead, 
2014). 
Significance of the Study 
Acute-care nurses have numerous modifiable risk factors for CVD (Lang et al., 
2012; Louie & Wedell, 2014; McElligott et al., 2009; Slater et al., 2005). Lang et al. 
(2012) found that acute-care nurses had elevated CVD due to the high rates of work-
related stress and negative social interactions between acute-care nurses and their 
supervisors. According to a study by Louie and Wedell (2014), who used data from the 
NHS, 60% of acute-care nurses who participated were obese or overweight and more 
than 50% of participants were severely inactive and had poor dietary habits. 
In the present study, I collected data from nurse participants in Georgia. The State 
of Georgia is one of the least healthy states in the United States (Hensley, 2014). Of 
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Georgians, 30% are obese and 76% have unhealthy diets (Hensley, 2014). In 2010, 
28.2% of deaths and 120,000 hospitalizations cost $5.5 billion, attributed to CVD and 
stroke in Georgia (Hensley, 2014). The total direct and indirect cost resulting from CVD 
in Georgia is about $7.5 billion annually (Hensley, 2014). Because CVD is more 
prevalent in the State of Georgia than elsewhere, acute-care nurses who work and reside 
in Georgia are likely to have CVD risk factors (Hensley, 2014). To date, no study has 
examined CVD risk factors of acute-care nurses in the Atlanta area. Further, no study has 
examined the association between CVD risk factors and pharmacogenetic testing in 
acute-care nurses. 
Social change can result from this study’s findings including a direct impact on 
nursing knowledge and training through the development of targeted educational 
materials for acute-care nurses (and ultimately, patients) about CVD risk factors and 
pharmacogenetic testing on patient health outcomes and on the empowerment of acute-
care nurses to act as patient advocates. Developing a better understanding of 
demographic and CVD risk factors among acute-care nurses will allow for specific 
intervention and targeted educational programs in nursing schools and training programs 
in healthcare organizations. Moreover, results from this study may facilitate future 
research on how acute-care nurses’ perceptions of CVD risk factors and pharmacogenetic 
testing influence their patient-care practices and patient advocacy, including increasing 
patient awareness and knowledge of CVD risk factors and the benefits of 
pharmacogenetic testing, 
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Summary 
CVD and pharmacogenetics related to CVD are relevant in the field of nursing 
due to the high prevalence of CVD in acute-care nurses (McElligott et al., 2009). Acute-
care nurses are knowledgeable about CVD, yet studies have documented that they are at 
risk (Lang et al., 2012; McElligott et al., 2009). Research has also shown that acute-care 
nurses have numerous risk factors for CVD (McElligott et al., 2009; Slater et al., 2005). 
Due to their increased risk for CVD, their lack of knowledge of pharmacogenetic testing, 
and their concerns about such testing, acute-care nurses may not be good role models in 
CVD risk reduction, which may impact their patient-education behaviors (Louie & 
Wedell, 2014). 
Hence, the need exists for this study as well as a better understanding of the 
literature presented in Chapter 2. Chapter 2 provides a comprehensive review of the 
theoretical framework guiding the study. Also, the chapter presents pertinent literature on 
acute-care nurses’ perceived risk for CVD, and their knowledge and attitudes toward 
pharmacogenetic testing. 
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Chapter 2: Literature Review 
Acute-care nurses carry an increased burden of CVD, and their perceptions of 
their own risk for CVD may play a role in their patient-centered communication, 
behaviors, and practices (Dodson, 2011, 2014). This increased focus on personalized 
healthcare has dovetailed with new and emerging genetic medicine models and practices, 
including pharmacogenetic testing for CVD. These practices are so new that researchers 
have yet to assess the various recommended pharmacogenetic methods, practices, and 
tests available to physicians, pharmacists, and acute-care nurses (Johnson & Cavallari, 
2013). Using Rosenstock’s (1974) HBM, I addressed the gaps in the literature by 
examining relationships between the independent variables of gender, highest level of 
education, and years of practice, and the dependent variables of perceived risk for CVD 
and knowledge of pharmacogenetic testing. I also examined the association between 
perceived risk for CVD and acceptance of pharmacogenetic testing in acute-care nurses. 
My objective in this chapter is to provide a review of the relevant literature as it 
pertains to the study topics. The chapter opens with a summary of the literature search 
strategy. A comprehensive review of the HBM follows, including discussions of HBM 
theoretical constructs and a summary of the HBM literature on acute-care nurses, CVD, 
and genetic testing. I then review CVD and risk factors for CVD, followed by a review of 
the literature on acute-care nurses’ risk factors for CVD. The chapter changes to a 
discussion and review of the pertinent literature on acute-care nurses’ knowledge and 
attitudes toward pharmacogenetic testing. As this literature is so new, studies reviewed 
addressed pharmacogenetic testing for any disease; not just CVD. A conclusion ends the 
chapter. 
26 
 
Literature Search Strategy 
The literature search for this study started with Walden University library and the 
use of ProQuest, which is linked to CINAHL, a cumulative index of Nursing and Allied 
Health Periodicals, Medline, PubMed, EBSCOhost, and Google Scholar. The search 
centered on peer-reviewed journal articles in the fields of nursing, medicine, psychology, 
and public health. The key terms used to search for relevant peer-reviewed journal 
articles included nurses health, acute care nurses’ health, nurses’ perceived risk for 
cardiovascular disease, acute care nurses and health risks, cardiovascular disease in 
healthcare providers, acute care nurses and cardiovascular disease, risk factors for 
cardiovascular disease in nurses, pharmacogenetic testing,  pharmacogenomic testing, 
healthcare and pharmacogenetic testing, nurses and pharmacogenetic testing, 
acceptance of pharmacogenetic testing, knowledge of pharmacogenetic testing, 
measurement of pharmacogenetic testing knowledge and attitudes, “attitudes toward 
pharmacogenetic testing, health belief model and nurses, and health belief model and 
pharmacogenetic testing. White papers, reports, data tables, and publications from 
national health organizations such as the World Heart Federation (WHF, 2014), AHA 
(2015), and CDC (2015) augmented empirical works. 
Theoretical Framework: Rosenstock’s (1974) Health Belief Model 
The theory that guided this research study was the HBM developed by 
Rosenstock and colleagues (i.e., Becker & Rosenstock, 1987; Cummings, Jette, & 
Rosenstock, 1978; Rosenstock, 1974; Rosenstock, Strecher, & Becker, 1994).  The 
underlying premise of the HBM is that perceptions of a disease and perceptions of a new 
health behavior are influenced by modifying factors to, in turn, influence likelihood of 
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action of engaging in a new health behavior (e.g., increased exercise) or change a 
negative health behavior (e.g., smoking cessation; Rosenstock, 1974; Rosenstock et al., 
1988, 1994). I discuss the components and constructs of the HBM in the following 
sections. 
Disease Perceptions: Perceived Susceptibility, Seriousness, and Threat 
Three components of the HBM pertain to the construct of perceptions of the 
disease. Two of these factors are the perceived susceptibility to or risk of acquiring a 
health issue and perceived severity or seriousness of a health issue (Rosenstock, 1974; 
Rosenstock et al., 1988, 1994). Perceived susceptibility pertains to an individual’s 
assessment of risk or likelihood of acquiring a health issue, disorder, or disease. 
Rosenstock (1974) argued that individuals who believe they are at greater risk than others 
in acquiring a disease are more likely to engage in behaviors that decrease this risk. 
Perceived seriousness refers to the individual’s thoughts and cognitions on the severity of 
a disease (Rosenstock, 1974; Rosenstock et al., 1988, 1994). Rosenstock (1974) posited 
that perceptions of the seriousness of health issues is most often informed by an 
individual’s knowledge and understanding of it. 
The third perception of the disease component is perceived threat of the health 
issue, which is considered a modifying factor (Rosenstock, 1974; Rosenstock et al., 1988, 
1994). The construct of perceived threat of a health issue has been neglected in 
theoretical conversations due to empirical inconsistency in its operational definition; 
indeed, some texts do not contain its definition nor do they describe this perception of the 
disease factor in any detail (Rosenstock et al., 1987, 1994). Perceived threat of the 
disease has been considered a response efficacy and has been used as a proxy for self-
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efficacy (Rogers, 1983); alternatively, it has been operationally defined as an extension of 
perceived susceptibility (Mikhail, 1981). The most consistent definition in the HBM 
literature of perceived threats is “a sequential function of perceived severity and 
perceived susceptibility” (Champion & Skinner, 2008, p. 47), which was the definition 
used in this study, considered a perception of the disease indicator. 
Health Behavior Perceptions: Perceived Benefits versus Barriers 
Two components concern perceptions of the new health behavior: the perceived 
benefits of a new health behavior and the perceived barriers or obstacles to adopting the 
new health behavior (Rosenstock, 1974; Rosenstock et al., 1988, 1994). Rosenstock 
(1974) posited that, when considering a new health behavior, individuals balance the 
perceived benefits with the perceived barriers, and these two components act together to 
increase the likelihood of action of adopting a new health behavior. The component of 
perceived benefits refers to individuals’ opinions of the value, importance, and usefulness 
of engaging in a certain health behavior to decrease the risk or likelihood of acquiring a 
disease or disorder. Simply stated, individuals are likely to adopt and continue engaging 
in a health behavior if they hold a firm belief in its efficacy in preventing a disease 
(Rosenstock, 1974). 
Perceived barriers pertain to individual obstacles that prevent an individual from 
adopting the new health behavior. Although some barriers are contextual (e.g., lack of 
financial or personal resources to obtain medical services), many are intrapersonal and 
can include fear, inconvenience, and distress of engaging in a new behavior (Rosenstock, 
1974; Rosenstock et al., 1988, 1994). Ultimately, an individual is more likely to take a 
health action if they perceive the benefits of the new health behavior outweigh the 
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barriers (Rosenstock, 1974; Rosenstock et al., 1988, 1994). As perceived benefits and 
perceived barriers pertain to the health behavior itself, knowledge of a health behavior 
can indicate this balance (Champion & Skinner, 2008). 
Modifying Factors 
The components that comprise the construct of modifying factors are individual 
factors. These include: (a) personal demographics, such as ethnicity, age, or gender, 
which were modifying factors examined in this study; (b) personality and psychological 
factors; and (c) prior experience with and knowledge of the disease, but not knowledge of 
the new health behavior (Rosenstock, 1974; Rosenstock et al., 1988, 1994). Modifying 
factors influence perceptions of the disease and perceptions of the health-behavior factors 
(Rosenstock, 1974; Rosenstock et al., 1988, 1994). 
Cues to Action 
Cues-to-action constructs are stimuli that elicit the decision-making process to 
adopt a new health behavior. Cues to action factors can be internal or external to the 
individual. Internal cues to action include disease symptomatology (e.g., fever or pain) 
whereas external cues to actions can be events, situations, or individuals who influence 
the individual to adopt a new health behavior (Rosenstock, 1974; Rosenstock et al., 1988, 
1994). Acute-care nurses themselves can act as cues to action in patient health behavioral 
change (McNeils et al., 2014). 
Relationships Between Health Belief Model Factors 
Rosenstock (1974) posited that modifying factors directly influence the 
perceptions of the disease variables of perceived susceptibility, perceived seriousness 
(severity), and perceived threat. Modifying factors also directly influence the perceptions 
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of perceived benefits and perceived barriers to new health behavior and inform the 
decision-making process when balancing perceived benefits with perceived barriers 
(Rosenstock, 1974). Perceptions of the disease and perceptions of the new health 
behavior in turn influence the likelihood of action: the adoption of a new health behavior 
or a change in health behavior (Rosenstock, 1974). I comprehensively discuss the 
theoretical relationships that this study addressed after a presentation of the literature on 
the HBM and acute-care nurses’ health behaviors. 
The Health Belief Model in Nursing Research 
The HBM is one of the most common theoretical frameworks used in health 
research (Bakas et al., 2012) and a substantial body of literature has been published on 
HBM-guided nursing interventions that promote health and prevent disease in patients 
(Boyde, Turner, Thompson, & Stewart, 2011; Heller et al., 2014; McNeils et al., 2014). 
The body of literature using the HBM to frame nurses’ own health behaviors is quite 
insubstantial, especially when considered in the context of CVD. Of the few studies that 
have used the HBM to advance understanding of nurses’ health behaviors, the majority 
have focused on nurses’ attitudes and behaviors about being vaccinated for influenza 
(Coe, Gatewood, Moczygemba, Goode, & Beckner, 2012; Ofstead, Tucker, Beebe, & 
Poland, 2008; Prematunge et al., 2012; Shahrabani et al., 2009; J. Zhang et al., 2010). 
Studies by Coe et al. (2012), Ofstead et al. (2008), and Prematunge et al. (2012) found 
significant associations between the HBM factors of perceived susceptibility and 
perceived seriousness of influenza and increased likelihood of getting vaccinated against 
influenza among nurses. Shahrabani et al. (2009), in a study with 299 Israeli nurses, 
found that perceived susceptibility and perceived seriousness of influenza significantly 
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predicted the likelihood of acute-care nurses getting an influenza vaccination. Results 
further showed that nurses’ increased knowledge of influenza, considered a modifying 
factor in the study, significantly predicted they would get vaccinated (Shahrabani et al., 
2009). 
J. Zhang et al. (2010) conducted a review of the literature of 12 studies that 
examined the relationships between HBM factors and nurses’ vaccination statuses. The 
overarching conclusions from the J. Zhang et al. (2010) review of studies, which were all 
correlational and used self-report data, was that as nurses’ knowledge of influenza and 
perceived seriousness of influenza increased, so did their likelihood of getting the 
influenza vaccination. Results further showed that acute-care nurses’ receipt of the 
influenza vaccine directly aligned with the increased likelihood that they would 
encourage their patients to receive the influenza vaccination (J. Zhang et al., 2010). This 
finding is relevant to this study, as it demonstrated that acute-care nurses’ own health 
behaviors align with advocacy for health behaviors in their patients. 
Other studies that used the HBM with nurse participants tended to focus on health 
promotion and preventative behaviors, such as cancer screenings (e.g., Yaren et al., 
2008); breast self-examinations (e.g., Tastan et al., 2011); hand washing (Ghanbari, 
Farazi, Shamsi, Khorsandi, & Esharti, 2014); and the prevention of workplace injuries 
(Tveito et al., 2014). Other studies conducted with nurses (Chan & Perry, 2012; Chi et al., 
2015) were evaluations of HBM-guided health-promotion interventions for nurses and 
their effects on nurses’ health behaviors. In a unique and rigorously designed 
randomized-controlled-trial (RCT) study with 100 Taiwanese pregnant nurses, Chi et al. 
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(2015) determined that participation in a second-hand smoking intervention resulted in 
nurses’ increased knowledge of and decreased exposure to second-hand smoke. 
The scarcity of HBM-guided intervention evaluation studies conducted with 
acute-care nurses as participants was evidenced in Chan and Perry’s (2012) review of the 
literature. Chan and Perry reviewed only three studies, found after Chan and Perry 
widened their literature search beyond RCTs to include any studies “that tested an 
appropriate intervention” with acute-care nurses (2012, p. 12). Of these three studies, 
none were methodologically rigorous. Researchers conducted the studies with three 
different nursing samples (in the United States, in Canada, and in Taiwan), which 
lessened the generalizability of findings. Furthermore, the three studies aimed to promote 
or decrease a variety of health behaviors (e.g., increased exercise, reduced smoking of 
cigarettes, or reduced use of alcohol). 
Despite these methodological concerns, Chan and Perry (2012) demonstrated that 
all three studies showed that nurses’ participation in health-promotion interventions 
resulted in significant changes in nurses’ health behaviors, including reduction in the 
number of cigarettes smoked per day and increased workplace exercise-based activity 
levels. The Chan and Perry study draws attention to the HBM theoretical relevance of 
studying nurses’ health behaviors as well as the dearth of HBM-driven studies on nurses. 
Health-belief model, nurses, and cardiovascular disease. Researchers 
conducted an overwhelming majority of studies using the HBM as a foundation to 
explore CVD-related interventions, practices, and behaviors with patients (e.g., Abed, 
Khalil, & Moser, 2015; Baghianimoghadam et al., 2013; Boyde et al., 2011). A general 
finding emerging from these studies was that increased knowledge of CVD risk factors 
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among patients did not significantly influence patients’ perceived susceptibility for CVD 
(Abed et al., 2015; Baghianimoghadam et al., 2013; Boyde et al., 2011). This body of 
literature showed that individuals who display numerous clinical indicators for CVD 
frequently perceived themselves to be at small to moderate risk for CVD (Abed et al., 
2015; Boyde et al., 2011). 
A gap in knowledge, however, exists with regard to nurses. A review of the 
literature yielded two HBM-guided studies (e.g., Hörnsten et al., 2014; Jones et al., 2006), 
one quantitative and one qualitative, conducted with acute-care and primary-care nurses 
and pertained to nurses’ own CVD-disease prevention behaviors. The Jones et al. (2006) 
study examined associations between modifying factors and perceived susceptibility and 
seriousness of CVD among 194 African American acute-care nurses who did not have 
CVD. Despite having risk factors for CVD (e.g., being of older age, overweight/obese, 
and sedentary) and considerable knowledge of CVD, acute-care nurses did not perceive 
themselves to be at risk for developing CVD. Although acute-care nurses who were older 
had more knowledge of CVD than did younger acute-care nurses, age did not moderate 
knowledge of CVD and increased perceived risk for CVD. The incongruence between 
perceptions of risk for and seriousness of CVD seen in the Jones et al. study suggested a 
need for theoretically driven studies on CVD risk factors among more diverse groups of 
acute-care nurses. The Jones et al. study focused only on female acute-care nurses; the 
researchers did not consider gender to be a modifying factor, nor were highest level of 
education or years of practice considered, which were examined as modifying factors in 
this study. 
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In contrast to Jones et al. (2006), Hörnsten et al. (2014) conducted a qualitative 
case study guided by the HBM and conducted with 10 primary care nurses in Sweden. 
The objective of the Hörnsten et al. study was not to examine primary-care nurses’ health 
behaviors as they related to CVD but rather healthcare provider–patient communication 
strategies that primary-care nurses used to promote health behaviors among patients who 
were at risk for CVD. Analysis of interviews yielded five themes centered on acute-care 
nurses’ communication practices with patients on CVD. The first theme concerned nurses’ 
acknowledgement of the importance of listening to patients’ concerns rather than 
directing and controlling the conversation. The second themes were the importance of 
instilling confidence and not fear in patients about their susceptibility to CVD. Two 
themes that shared commonalities were (a) guiding patients toward better lifestyle 
choices rather than pressuring them to change poor health behaviors and (b) engaging in 
motivational communication practices that encourage lifestyle changes among patients 
rather than demanding patients take responsibility for their behaviors. The last theme was 
that primary-care nurses played a key role in promoting patients’ communication 
regarding psychologically distressing health topics with their healthcare provider rather 
than patients avoiding such topics (Hörnsten et al., 2014). 
Health-belief model, nurses, and genetic testing. Although somewhat dated, the 
review of the literature on healthcare provider–patient communication practices regarding 
genetic testing by Edwards (2009) is a meaningful and relevant empirical work that had 
implications for the present study. The goal of the Edwards study was to systematically 
review literature on healthcare provider–patient communication on genetic testing and its 
influence on patient outcomes. Edwards focused on studies that avoided the topic of 
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genetic counseling and instead specifically addressed healthcare provider–patient “risk 
communication” interventions for genetic testing, or “the open two-way exchange of 
information and opinion about risk, leading to better [patient] understanding and better 
[healthcare provider-driven] decisions” (p. 4). 
The Edwards (2009) review of literature included studies that ranged from 
rigorously designed RCTs to qualitative case studies of genetic-testing information 
exchanges or interventions, resulting in a total of 28 studies. The majority (> 80%) of 
studies involved genetic counselors or psychologists as healthcare providers. To increase 
the number of studies reviewed, Edwards included studies that focused on the efficacy of 
any type of “genetic testing intervention,” inclusive of RCTs, face-to-face informational 
meetings between a healthcare professional and a patient, risk assessments, “pedigree 
construction,” videos, and interactive digital products (2009, p. 17). The type of specific 
genetic-testing interventions included general psychosocial counseling, psychosocial 
counseling specific to a patient-outcome domain (e.g., stress management, problem 
solving, or decision making), “cognitive-affective preparation” concerning a negative 
genetic-testing outcome, and basic informational sessions (Edwards, 2009, p. 18). 
Edwards (2009) compared studies and noted those where the interventions were 
effective and feasible. The researchers also examined the influence of the intervention on 
patient outcomes. Patient outcomes varied, as the interventions differed in intent. For 
example, some studies examined interventions that focused on patients’ interest in 
receiving genetic testing (e.g., for a specific disease, such as breast cancer) whereas other 
studies addressed interventions to assist patients with a newly diagnosed genetic 
condition found through genetic testing. The most common dependent variables 
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examined were (a) patient knowledge and understanding of the outcomes of a genetic test, 
conducted for themselves or for a family member (e.g., a child with Down syndrome); 
(b) patient perceived risk of developing a genetic-based disorder or disease risk (e.g., 
breast cancer due to having the BRCA1/2 gene mutation); and (c) patient-perceived 
health-behavior change (e.g., undergoing BRCA1/2 testing, mammography, or breast 
examination; Edwards, 2009). 
Despite the varied types of studies reviewed, Edwards (2009) did find consistency 
in results with regard to significant and positive associations between risk-
communication interventions and increases in patients’ disease and genetic-testing 
knowledge and perceived risk for acquiring a disease. However, risk-communication 
interventions did not systematically influence patient affective states, health status, or 
health behavior change. Edwards also found that patient characteristics of “low-to-
moderate risk” status and higher levels of education aligned with increased 
responsiveness to participation in risk-communication interventions (p. 18). 
One assumption of the HBM is that individuals have the capacity to change their 
health-related behaviors for health promotion and disease prevention (Rosenstock, 1974; 
Rosenstock et al., 1988, 1994). The body of literature on the HBM supports an additional 
argument that not only do acute-care nurses have the ability to influence others’ health 
behavior by increasing their knowledge of a disease or genetic testing, but they 
themselves would be more accepting of the adoption of new health behaviors (Johnson & 
Cavallari, 2013). In other words, if acute-care nurses are knowledgeable enough about 
pharmacogenetic testing through acceptance and awareness, they would be able to teach 
their patients about this new technology. 
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Application of the Health Belief Model to the Proposed Study 
The present study focused on (a) the modifying factors of gender, highest level of 
education, and years of practice; (b) perceived susceptibility or risk for CVD; 
(c) perceived benefits versus barriers to health behavior, measured as knowledge of 
pharmacogenetic testing for CVD; and (d) likelihood of action, measured by acceptance 
of pharmacogenetic testing for CVD. Figure 2 presents the pathways examined in this 
study. The pathway from modifying factors to perceived susceptibility, Path A, was 
addressed by Research Questions 1 through 3. These three research questions inquired if 
acute-care nurses’ gender, years of education, and years of practice (the independent 
variables) significantly influence perceived susceptibility for CVD (the dependent 
variable). The pathway from modifying factors to perceptions of benefits over barriers, 
Path B, was addressed in Research Questions 4 through 6. These three questions inquired 
if acute-care nurses’ gender, years of education, and years of practice (the independent 
variables) significantly influenced their knowledge of pharmacogenetic testing for CVD 
(the dependent variable). The final pathway between the perceived susceptibility to 
likelihood of action, Path C, inquired as to whether perceived susceptibility for CVD 
significantly influenced the likelihood of the action behavior of accepting 
pharmacogenetic testing for CVD. 
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Figure 1. Proposed study pathways using the HBM (Note. This figure was created 
specifically for the study) 
 
Cardiovascular Disease 
CVDs are diseases that affect the heart and blood vessels such as ischemic heart 
disease, cerebrovascular disease (stroke), heart failure, and coronary artery disease (CDC, 
2015). Mortality and morbidity associated with CVD in the United States has diminished 
drastically as a result of improvement in disease prevention, diagnoses, and treatment 
options. Although CVD incidence has diminished, it still impacts the health and well-
being of many Americans. Three major risk factors associated with CVD are 
uncontrolled hypertension, elevated cholesterol levels, and smoking. In 2007–2008, 
49.7% of individuals aged 20 years or older had at least one of the risk factors associated 
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with CVD, 21.3% had the two of three risk factors, and 2.4% had all three risk factors 
associated with CVD. Nationally, CVD causes one in three deaths each year (CDC, 2015). 
Cardiovascular Risk Factors 
Despite the high incidence of CVD, CVD has declined from 6.7% in 2000 to 
6.0% in 2010 (CDC, 2015). The drop in CVD is partly due to recognition of the risk 
factors for CVD (CDC, 2015; Go et al., 2013; WHF, 2014). However, some risk factors 
cannot be changed; that is, they are inherent to the individual and are unmodifiable. Other 
risk factors for CVD can be changed, and are considered modifiable (CDC, 2015; Go et 
al., 2013; Roger et al., 2012: WHF, 2014). 
Unmodifiable cardiovascular disease risk factors. The most common 
unmodifiable risk factors are age, gender, family history, and ethnicity (CDC, 2015; 
Roger et al., 2012). Studies (Berry et al., 2012; Go et al., 2013; Lang et al., 2012) and 
public health reports (CDC, 2015; WHF, 2014) have consistently documented significant 
associations between aging and increased risk of developing CVD. Subtle physiological 
changes can occur in the cardiovascular system even in the absence of CVD (AHA, 2015; 
Roger et al., 2012; WHF, 2014). Aging aligns with advanced growth of plaque 
formations that result from genetic or lifestyle factors (Go et al., 2013; Qi, Meigs, 
Rexrode, Hu, & Qi, 2013). Moreover, among older individuals, the heart muscles relax 
less completely between beats, stiffening the heart chamber and lessening its 
effectiveness in pumping blood throughout the body (AHA, 2015; Go et al., 2013; Roger 
et al., 2012). 
It is difficult to discuss unmodifiable risk factors in isolation from one another: 
aging, gender, ethnicity, and family history all interact to influence risk for CVD (CDC, 
40 
 
2015; Cho & Lee, 2012). A report on CVD by age, gender, and ethnic groups by the 
AHA (2015) documented that 6.3% of U.S. men and 5.6% of U.S. women aged 40 to 59 
years of age have CVD. These percentages increase to 19.9% and 9.7% for men and 
women aged 60 to 79 years of age, respectively (AHA, 2015). However, male gender 
aligns with increased likelihood of CVD only when comparing men to nonmenopausal 
women (Cho & Lee, 2012; WHF, 2014). When women reach menopausal age, the risk of 
CVD equals that of men (Cho & Lee, 2012; WHF, 2014). The increased likelihood of 
CVD for women after menopause has been credited to loss of estrogen (Cho & Lee, 
2012; Crandall & Barrett-Connor, 2013). Moreover, postmenopausal women have 
significantly higher levels of obesity and hypercholesterolemia than do men of the same 
age; obesity and hypercholesterolemia are modifiable risk factors for CVD (ANA, 2015; 
Baum et al., 2012; Go et al., 2013). Nonetheless, studies have shown that African 
American men have the greatest risk for CVD in comparison to African American 
women and Caucasian men and women, and remain at greatest risk across age groups 
(AHA, 2015; Go et al., 2013). 
Modifiable cardiovascular disease risk factors. Modifiable risk factors are 
those factors that can be controlled and treated such as high blood pressure, elevated 
cholesterol, overweight, tobacco use, sedentary lifestyle, poor diet, and diabetes; in other 
words, those risks that can be changed or modified through behavioral change (AHA, 
2015; Roger et al., 2012; WHF, 2014). Medical treatment has little impact in preventing 
premature death. However, individuals can prevent premature death by preventing 
unhealthy habits, which accounts for 40% of all premature deaths (AHA, 2015; Roger et 
al., 2012; WHF, 2014). 
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Hypertension. Hypertension is the leading cause of CVD globally, determined by 
constant elevation of systolic pressure (the top number) at 140 millimeters of mercury or 
higher (when the heart is at work) or when diastolic (the bottom number) pressure is 90 
millimeters of mercury or above (when the heart is at rest; CDC, 2015; Louie & Wedell, 
2014; Roger et al., 2012). Prehypertension is when systolic blood pressure is 120–139 
mm Hg or diastolic blood pressure of 80–89 mm Hg (CDC, 2015; Louie & Wedell, 2014). 
According to the CDC (2015), hypertension is a leading CVD-risk factor. Lack of 
physical activity, poor diet, and heavy smoking can lead to uncontrollable hypertension, 
hence CVD risk (Go et al., 2013; Roger et al., 2012). 
Smoking. According to the World Health Organization (WHO, 2015), 
approximately 1 billion people in the world smoke and as such, the risk of being 
diagnosed with CVD is extremely high among female smokers, younger male smokers, 
and heavy smokers, and smoking causes about 10% of all CVD deaths. In the United 
States, 350,000 men and 80,000 women die prematurely each year from CVD as a result 
of smoking (Louie & Wedell, 2014; WHO, 2015). By 2020, smokers will increase their 
rate of smoking to 6.7 trillion cigarettes globally, and by 2030 tobacco-related deaths will 
increase to 80% of all deaths (Lang et al., 2012; WHO, 2015). 
Elevated cholesterol/Poor diet. Elevation of blood-level cholesterol remains one 
CVD risk factor and causes 2.6 million deaths (4.5% of all CVD deaths globally; Mendis, 
Puska, & Norrving, 2011). The incidence of CVD has increased significantly due to 
changes in dietary habits. In a study conducted by Burke, Thompson, Roos, Verdouw, 
and Troe (2011) about CVD prevention, the consumption of foods high in fats, processed 
foods, and simple sugars has increased the development of CVD. In the same study, 
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researchers found an increase of 250 kcal intakes per capita per day and also an increase 
in fat intake per capita per day of 14 grams (Burke et al., 2011). This suggests that diet 
rich in fruits and vegetables, water, and less salt intake will improve cardiovascular 
health (Roger et al., 2012). 
Diabetes. Diabetes mellitus is one of the modifiable risk factors associated with 
CVD affecting more than 16 million individuals in the United States alone (Louie & 
Wedell, 2014),for those with the two types of diabetes—type 1 and type 2—individuals 
have twice the chance of being diagnosed with CVD. CVD mortality occurs more in 
individuals diagnosed with diabetes. The risk factor for type 2 diabetes is being obese, 
coupled with lack of exercise and poor diet. In the NHS, 60% of participants (acute-care 
nurses) were obese or overweight; more than 50% were severely inactive and had poor 
dietary habits (Louie & Wedell, 2014). 
Overweight/Obesity. Obesity, indicated by a body mass index equal or greater 
than 30, is one of the strongest predictors of CVD (Louie & Wedell, 2014). Excessive 
body weight significantly impacts other CVD risk factors such as hypertension, low-
density lipoprotein, triglycerides, and diabetes. These lead to increased risk of CVD, 
hence premature death (Louie & Wedell, 2014). In several epidemiological studies, 
overweight individuals have a 32% chance of being diagnosed with CVD and obese 
individuals have an 81% chance (Alexander, 2001). In a meta-analysis of 26 
observational studies, (390,000 men and women) conducted at the Harvard School of 
Public Health, “women with a body-mass index of 30 or higher had 62% greater risk of 
dying from [coronary artery disease] and CVD” (Alexander, 2001, p. 45). 
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Cardiovascular Disease Risk Factors and Genetics: Nurses’ Health Study Research 
As stated previously, family history is an unmodifiable risk for CVD (AHA, 
2015; Louie & Wedell, 2014), and 43% of American adults have a family history of CVD 
(Zlot, Valdez, Han, Silvey, & Leman, 2010). Family history as a risk factor for CVD has 
led to studies examining the roles genes play in the development of CVD, with much of 
this research recognizing the complex interaction among genotypes, the individual, and 
the environment (J. Zhang et al., 2010). Studies that have used Harvard’s NHS data (e.g., 
Baum et al., 2012; Crandall & Barrett-Connor, 2013; de Oliveira Otto et al., 2013; Fretts 
et al., 2014; Qi et al., 2013) are at the forefront of this literature. Most researchers using 
NHS data tend to identity participants as women and not acute-care nurses; therefore, it is 
important to acknowledge that results from studies pertain to women and to acute-care 
nurses. 
The contribution of NHS research studies to the understanding of genetic and 
physiological contributions to CVD cannot be overstated. Studies using NHS data are 
expansive and comprehensive, with numerous studies examining various genetic 
antecedents of CVD. This has led to some consistencies in the findings. Contemporary 
studies using NHS data shown significant and consistent associations between shortened 
telomere length and increased risk for CVD (Crous-Bou et al., 2014; Devore, Prescott, 
De Vivo, & Grodstein, 2011; Du et al., 2013; Gu et al., 2015). Studies using NHS data 
led to increased knowledge of the genetic variants involved in phospholipid synthesis 
(Ferrell & Chiang, 2015, Fretts et al., 2014), inflammatory and fatty-acid processes 
(Baum et al., 2012; de Oliveira Otto et al., 2013; Hak, Karlson, Feskanich, Stampfer, & 
Costenbader, 2009), and glucose and estrogen regulation (Burns & Korach, 2012; 
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Crandall & Barrett-Connor, 2013; Qi et al., 2013; Qi, Workalemahu, Zhang, Hu, & Qi, 
2012; H. Zhang, Mo, Hao, & Gu, 2012), all of which increase the odds of having CVD. 
With consistent acknowledgement of the genes-environment complexities 
involved in the development of CVD, the body of literature using NHS has contributed to 
the practice of patient-centered practices by identifying individuals at risk for CVD, as 
well as behaviors that reduce CVD risk (Squassina et al., 2010). Results from NHS 
studies showed that the risk for CVD is more likely among women (and nurses) with 
(a) metabolic syndrome and Type 2 diabetes (Du et al., 2013; Ferrell & Chiang, 2015; 
Kalea, Harrison, Stephens, & Talmud, 2012; Qi et al., 2013, 2012; Stanhope, Schwartz, 
& Havel, 2013); (b) estrogen-related disorders, including early menopause (Burns & 
Korach, 2012; Crandall & Barrett-Connor, 2013; Shuster, Rhodes, Gostout, Grossardt, & 
Rocca, 2010); (c) depression (Hek et al., 2013); (d) sleep disorders, including sleep apnea 
and restless leg syndrome (Ferrell & Chiang, 2015; Innes, Selfe, & Agarwal, 2012; 
Sharma et al., 2011); (e) Vitamin B and D deficiencies (Bartali, Devore, Grodstein, & 
Kang, 2014; Gunta, Thadhani, & Mak, 2013; Willett, 2012); and (f) certain auto-immune 
disorders (e.g., rheumatoid arthritis, Karlson et al., 2013, Solomon et al., 2003; and lupus, 
Hak et al., 2009). Results from the Huertas-Vazquez et al. (2013) study, which used NHS 
data, documented potential linkages between schizophrenia and increased risk for CVD 
resulting from a neuregulin 1 genetic mutation. Studies using NHS data have additionally 
provided support that CVD risk can be reduced by (a) eating a Mediterranean diet 
(Crous-Bou et al., 2014; Gu et al., 2015; Hindy et al., 2014); (b) reducing the intake of 
foods high in fats and fructose (Stanhope et al., 2013; Willett, 2012); (c) engaging in 
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exercise (Archer & Blair, 2011; Du et al., 2013); and increasing coffee intake (Freedman, 
Park, Abnet, Hollenbeck, & Sinha, 2012). 
Cardiovascular Disease Risk Factors Among Nurses 
Nurses are knowledgeable about CVD, yet studies have documented that they are 
at risk for CVD (Lang et al., 2012; McElligott et al., 2009). According to the Department 
for Professional Employees (DPE, 2012), 91.1% of RNs and 93.4% of licensed practical 
nurses were women. The mean age of nurses as of 2011 was 50 years (Nahm et al., 2012). 
The high prevalence of female nurses and the aging of nurses increase the likelihood that 
individuals in this white-collar profession are at greater risk for CVD compared to those 
in other professions (DPE, 2012; McElligott et al., 2009; Nahm et al., 2012). Family 
history of CVD is another demographic risk factor (CDC, 2015). Fair et al. (2009), in a 
study of CVD risk factors in nurses, found that more than 20% of nurses in the study had 
a family history of premature death from CVD. The percentage of nurses with a family 
history of early onset CVD was 34.2% in the Puett et al. (2009) study using NHS data. 
High rates of CVD risk factors exist among nurses across the health, mental 
health, health-related behaviors, and demographic-risk domains, which can negatively 
impact people’s health and well-being (ANA, 2015; Baer et al., 2011; Fair et al., 2009; 
Khan et al., 2012). A major risk factor for CVD among nurses is obesity (ANA, 2015). In 
a study by Louie and Wedell (2014) using NHS data, 60% of acute-care nurses in the 
study were obese or overweight. In a recent study by the ANA (2015), the percentage of 
nurses who were obese was a disconcerting 70%. Associated with obesity are a sedentary 
lifestyle and poor dietary habits (ANA, 2015). 
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Across studies examining CVD risk factors in nurses, results showed that, on 
average, 11% of nurses have diabetes; higher that the average percentage of 9% for U.S. 
adults (Khan et al., 2012; Preventive Cardiovascular Nurses Association, 2008). The 
percentage of nurses with hypertension in studies has ranged from approximately 18% to 
over 40%, and the percentage of nurses with elevated cholesterol levels has ranged from 
15% to 50% (Khan et al., 2012; Lang et al., 2012; Puett et al., 2009). Baer et al. (2011) 
and Li et al. (2006), using data from the NHS, concluded that obesity, diabetes, 
hypertension, and high cholesterol significantly aligned with increased risk of mortality 
due to CVD among nurses. 
Pharmacogenetic and Pharmacogenetic Testing 
Pharmacogenetics, which “blends components of the disciplines of genetics and 
pharmacology,” refers to the study of genetic variations of individuals that affect drug 
metabolism (Johnson & Cavallari, 2013, p. 987). The premise of pharmacogenetics is that 
genetic variability can results in two types of drug reactions related to pharmacokinetics, 
or the effects of a dosage of the drug and pharmacodynamics, or the effects of the drug 
itself on the body (Howland, 2012; Johnson & Cavallari, 2013). Pharmacokinetics and 
pharmacodynamics assist in the clinical understanding of (a) drug concentration, 
metabolism, and clearance; (b) drug dosage needed for clinical affect; and (c) the 
likelihood of an adverse drug reaction (Blakey & Hall, 2011; Howland, 2012). 
Pharmacogenetic is a prime example of personalized medicine (Johnson & Cavallari, 
2013; Scott, 2011). “Personalized medicine entails engagement between patient and 
health care provider, identification of relevant genetic variations for implementation, 
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assay reliability, point-of-care decision support, and necessary institutional investments” 
(Scott, 2011, p. 987). 
Pharmacogenetic research has existed for more than 60 years, with the term 
pharmacogenetic coined in 1959. Until the late 1990s, most pharmacogenetic studies, 
uncommon in the literature, focused on DNA sequencing to identify patients who might 
respond differently to medications (Johnson & Cavallari, 2013; Squassina et al., 2010). 
Advances in the understanding of genetics, the growth of specialized technology for 
medicine, the high rates of CVD, and the advent of personalized medicine contributed to 
the emergence of pharmacogenetic research related to major cardiovascular medications 
in the late 2000s (Scott, 2011), with much work conducted on CVD drugs such as 
antiplatelet agents, warfarin, statins, beta blockers, diuretics, as well as antiarrhythmic 
agents (Kadafour et al., 2009; Musunuru et al., 2012; Roden, 2012; Van Schie et al., 
2012; Verschuren et al., 2011). 
The study conducted by Frazier et al. (2005) stressed that knowledge of genetic 
components of CVD (such as cardiomyopathy and heart failure) in conjunction with 
pharmacogenetics can improve cardiovascular nursing care. Heart failure is the decreased 
ability of the heart to fill and to eject adequate blood to the entire body. Cardiomyopathy 
is the second highest cause of sudden cardiac death in the United States; the primary 
cause of cardiomyopathy is genetic disposition (Frazier et al., 2005). For instance, 
patients with ischemic heart disease with genotypes associated with poor prognosis 
respond well to statins (Kadafour et al., 2009; Verschuren et al., 2011). Patients with a 
gene that encodes angiotensin converting enzymes and β₁-adrenergic receptors respond 
less well to cardiovascular drugs (Verschuren et al., 2011). 
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Nurses’ Knowledge of Pharmacogenetic Testing 
To effectively communicate with patients about pharmacogenetic testing, it is 
important that healthcare providers have at least adequate levels of knowledge of 
pharmacogenetic testing: “patients demand accurate and timely information … about … 
pharmacogenetic testing and what the results mean” (Payne & Annemans, 2013, p. 20). 
Results from the minimal body of literature on healthcare providers’ knowledge of 
pharmacogenetic testing (e.g., Bannur, Bahaman, Salleh, & Kek, 2014; Moen & Lamba, 
2012; Roederer et al., 2012; Stanek et al., 2012) showed that physicians and pharmacists 
lack such knowledge. The knowledge of pharmacogenetic testing among nurses is even 
less understood. 
The body of literature on nurses’ knowledge of pharmacogenetic testing is small 
but growing. Some studies (e.g., Dodson, 2011; Dodson & Van Riper, 2011; Haga & 
LaPointe, 2013; Haga, O’Daniel, Tindall, Lipkus, et al., 2012) included various 
healthcare providers, including nurses, as participants. The focus of the Haga, O’Daniel, 
Tindall, Lipkus, et al. (2012) and Haga, Tindall, & O’Daniel (2012) qualitative studies 
were to examine differences between primary care and genetics in healthcare 
professionals’ knowledge of pharmacogenetic testing specific to CVD. Of the 21 
participants, 11 were primary-care providers and 10 were genetics healthcare 
professionals. Participants included nurse practitioners, but not nurses, in both groups. 
From focus-group data, specific themes emerged surrounding differences between 
primary care and genetics healthcare providers’ knowledge of pharmacogenetic testing. 
Nurse practitioners conceded their lack of knowledge of pharmacogenetic testing, and did 
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so at a greater degree than did primary-care physicians (Haga, O’Daniel, Tindall, Lipkus 
et al., 2012; Haga, O’Daniel, Tindall, Mills et al, 2012). 
Dodson (2011) conducted a review of the literature on healthcare providers’ 
knowledge of pharmacogenetic testing that included studies conducted with nurses. 
Dodson (2011) reviewed 12 studies, the oldest published in 1999, equally divided across 
quantitative and qualitative methodologies, and 50% were conducted in the United States. 
Notable findings were that a substantial majority—66% to 84%—of healthcare providers, 
including nurses, reported having minimal knowledge of pharmacogenetic testing. No 
differences emerged in knowledge between nurses and pharmacists. 
Dodson extended this work with a follow-up study (Dodson & Van Riper, 2011) 
conducted with 184 healthcare providers, of which 75 were RNs and 35 were nursing 
students. The researchers asked participants to respond to a series of open-ended 
questions about pharmacogenetic testing, and analyzed responses using content analysis. 
Many of the four themes that emerged provided examples as to how the (lack of) 
knowledge of pharmacogenetic testing impaired healthcare providers’ patient-centered 
practices. The first theme concerned healthcare providers’ negative concerns regarding 
pharmacogenetic testing. Decreased knowledge of pharmacogenetic testing often led to 
healthcare providers’ perceptions that pharmacogenetic testing itself was inaccurate, 
unreliable, or impractical. The second theme concerned the lack of successful integration 
of pharmacogenetic testing into general healthcare practices. The lack of knowledge of 
pharmacogenetic testing led to increased resistance among healthcare providers to 
educate themselves on and increase their knowledge and use of pharmacogenetic testing. 
Much of this resistance stemmed from healthcare providers’ perceptions that 
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pharmacogenetic testing was too new and novel to be meaningful to their current patient 
practices (Dodson & Van Riper, 2011). 
The third and fourth themes found in the study by Dodson and Van Riper (2011) 
focused on patients, specifically with regard to patient healthcare disparities and potential 
harm of pharmacogenetic testing to patients. A majority (80%) of the 75 RNs in the study 
noted concerns that, as seen with other medical advances, availability and access to 
pharmacogenetic testing would be limited to those who could afford it, thereby 
“exacerbating disparity” between high- and low-income healthcare consumers (Dodson 
& Van Riper, 2011, p. 536). In turn, the disparity in availability and access to 
pharmacogenetic testing may result in “two different standards of care”: one for the 
wealthy and one for the poor (Dodson & Van Riper, 2011, p. 536). Aligned with these 
disparities was the potential harm of pharmacogenetic testing: healthcare providers 
voiced concerns that pharmacogenetic testing could cause more harm than benefit to 
patients. Perceptions of harm included (a) increased healthcare costs for patients; 
(b) prolonging the life of patients who had very poor quality of life; (c) physician reliance 
on testing, resulting in “less vigilance” in monitoring, for example, medication reactions; 
and (d) increasing patient distress, anxiety, and fear of genetic conditions or genetic-
based diseases (Dodson & Van Riper, 2011). 
Fewer studies (e.g., Blakey & Hall, 2011; Godino & Skirton, 2012; Kadafour et 
al., 2009; Van Riper et al., 2011) focused exclusively on nurses. Results from these 
studies reiterated the lack of knowledge of pharmacogenetic testing among nurses as well 
as the possible consequences that may occur as a result of this lack of knowledge. Blakey 
and Hall (2011), in a study conducted with British nurses, found that a major challenge 
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for nurses was to explain results from pharmacogenetic testing to patients, who required 
expert knowledge on genetics and pharmacogenetic; knowledge nurses reported not 
having. Results from the Kadafour et al. (2009) study suggested that lack of knowledge 
of pharmacogenetic testing may prevent nurses from participating in studies on the topic: 
of the 2,038 nurses recruited for the study, only 448 (22%) completed the study. 
Moreover, of these 448 nurses, 40% reported being unclear as to the clinical benefits of 
pharmacogenetic testing (Kadafour et al., 2009). The most concerning result was that the 
average pharmacogenetic-testing-knowledge score among nurses was 40% (Kadafour et 
al., 2009). 
Although not examining nurses’ knowledge of pharmacogenetic testing per se, 
Godino and Skirton (2012) conducted a systematic review of the literature on nurses’ 
knowledge of genetics. Godino and Skirton’s review of the literature shared similarities 
to previous literature reviews discussed in a chapter by Edwards (2009) and Dodson 
(2011). Godino and Skirton retrieved only six relevant studies, and even with this small 
number of articles, considerable variability existed in location (e.g., three studies were 
conducted in the United States, three each in Scotland, Singapore, and Canada). The 
review was, however, strengthened by its focus on quantitative descriptive cross-sectional 
studies that used nurse participants, had the singular aim of providing descriptions of 
nurses’ level of knowledge on genetics, and measured nurses’ perceived knowledge of 
genetics. Results from Godino and Skirton’s study replicated previous findings in that, 
across studies, nurses’ knowledge of genetics was poor. 
The most comprehensive study on nurses’ knowledge of pharmacogenetic was 
conducted by Van Riper et al. (2011) with 560 RNs. Although the initial intent of the 
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study was to determine nurses’ knowledge of pharmacogenetic as it pertained to CVD, 
the study expanded to include other pharmacogenetic topics. Results from the Van Riper 
et al. study reiterated those found in previous studies (e.g., Dodson, 2011, 2014, 2015; 
Kadafour et al., 2009). A third (33%) of nurses reported their understanding of 
pharmacogenetic as poor and 44% reported their knowledge as fair. Most concerning was 
the performance on tests that gauged knowledge of pharmacogenetic testing: the mean 
score of the 10-item test was 60.3%, equivalent to a grade of D. Only 33% of nurses 
correctly responded with true when answering the statement, “genetic determinants of 
drug response change over a person’s lifetime” (Van Riper et al., 2011, p. 7). 
Nurses’ Attitudes about Pharmacogenetic Testing 
One important factor influencing a successful implementation of pharmacogenetic 
testing is nurses’ attitudes toward it: these attitudes often determine their behavior in 
caring for the patients (Chadwell, 2013; Dodson, 2011, 2014, 2015). The literature on 
nurses’ attitudes toward pharmacogenetic testing is somewhat less robust than the 
literature on nurses’ knowledge, with much of the empirical work done by Dodson (2011, 
2014, 2015) and Haga and colleagues (Haga, Kawamoto, Agans, & Ginsburg, 2011; 
Haga & LaPointe, 2013; Haga & Mills, 2015; Haga, O’Daniel, Tindall, Lipkus et al., 
2012, ; Haga, O’Daniel, Tindall, Mills et al. 2012; Mills & Haga, 2013). Despite the 
dearth of such studies, results from these studies have consistently documented that 
ethical issues and advantages of testing are central concerns among nurses (Dodson, 
2011, 2014, 2015; Haga et al., 2011; Haga & LaPointe, 2013; Haga & Mills, 2015). 
These two attitudinal issues are discussed in the following sections. 
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Pharmacogenetic testing: Ethical issues. In the era of the Affordable Care Act, 
patient-centered care, and genomic medicine, numerous issues surround pharmacogenetic 
testing (Dodson, 2011). In Dodson’s (2011) review of the literature, eight of the 11 
articles reported nurses’ ethical concerns about testing; the most frequent being 
employment and insurance discrimination based on the individual’s pharmacogenetic 
testing profile. Ethical issues emerged as a primary issue in the Van Riper et al. (2011) 
study; with 47% of the nurses expressing concern that pharmacogenetic testing would 
result in employment and insurance discriminatory practices. Ethical issues regarding 
pharmacogenetic testing have been so concerning to nurses and other healthcare 
providers that in numerous studies, nurses and other providers have voiced a need for 
informed consent for this type of testing (Bartlett, 2011; Dodson, 2011, 2014, 2015). As 
stated by Bartlett (2011), “patients (accepted) pharmacogenetic testing (when) their rights 
to consent and privacy were fully protected” (p. 27). 
At issue is whether patients’ genetic information would be given to their 
employers, health-insurance representatives, and other agencies and individuals (Bartlett, 
2011). According to Haga and Burke (2008) and Haga et al. (2011), pharmacogenetic 
testing does not have comprehensive reimbursement of companion diagnostics, even 
when recommended by the Food and Drug Administration. Health-insurance 
representatives are quite reluctant to reimburse for pharmacogenetic testing as they claim 
that its clinical usefulness coupled with knowledge of pharmacogenetic is very 
questionable (Haga & Burke, 2008; Haga et al., 2011; Haga & LaPointe, 2013). For 
instance, for warfarin, a CVD medication, individuals with a particular enzyme activity 
called CYP2C9 need a reduced dose and require constant monitoring of their blood level 
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to prevent bleeding (Bannur et al., 2014). In view of this problem, the Food and Drug 
Administration mandated genotyping for all patients prior to issuing a warfarin 
prescription; this poses significant challenges when insurers do not reimburse for the 
companion testing (Haga et al., 2011). 
Despite the benefits associated with pharmacogenetic testing, doctors, nurses, 
pharmacists, and other healthcare professionals face ethical dilemmas regarding who 
should be tested and the appropriateness of testing in conjunction with treatment options 
(Calzone et al., 2010). Shin et al. (2009) maintained that the lack of availability of 
pharmacogenetic testing for patients and the high cost, as well as the lack of 
reimbursement, all impede the introduction of pharmacogenetic testing in the healthcare 
arena. Only 8% of laboratories in the United States can competently perform the 
pharmacogenetic tests needed for patient care, which eventually caused a much longer 
turnaround time for needed test results (Calzone et al., 2010). Because turnaround time 
might take several days or weeks, the safety and well-being of patients is compromised if 
the test result is needed immediately for clinical decision making, as in the case of 
warfarin dosing for anticoagulation purposes. The average cost of pharmacogenetic 
testing ranges from $250 to $500. Insurers tend to reimburse only a few of these tests, as 
the majority of them are considered experimental (Calzone et al., 2010). 
Pharmacogenetic testing: Advantages. The second theme seen in the literature 
on nurses’ attitudes about pharmacogenetic testing pertained to its perceived advantages. 
The most frequently reported advantage reported by nurses was the reduced likelihood of 
patient adverse reactions to drugs (Dodson, 2011, 2015). Haga et al. (2011) and Haga and 
Mills (2015) reported similar findings. Van Riper et al. (2011) also examined attitudes 
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toward pharmacogenetic testing among nurses and their results were quite similar to 
those found by Dodson (2011). In contrast to Dodson (2011), who reported one primary 
advantage of pharmacogenetic testing (i.e., reduced adverse reactions to medications), 
Van Riper et al. elicited additional advantages from nurses: (a) decreased drug reactions 
in general, (b) decreased drug reactions to CVD medications, (c) reduced time needed to 
titrate a CVD medication, and (d) decreased costs of pharmacogenetic-derived 
medications. 
A criticism of the research on attitudes toward pharmacogenetic testing, as well as 
the research on knowledge, is that most studies used a descriptive cross-sectional 
research design or were reviews of literature, resulting in a gap in the literature 
concerning antecedents of nurses’ knowledge of pharmacogenetic testing. In Dodson’s 
(2014) seminal study, the researcher examined work-based, demographic, and personality 
antecedents of pharmacogenetic testing knowledge and attitudes of 368 oncology acute-
care nurses in North Carolina. Results showed that various factors influenced 
pharmacogenetic testing knowledge and attitudes among acute-care nurses. Although 
experience and exposure to pharmacogenetic testing led to increased knowledge and 
acceptance of pharmacogenetic testing among nurses, nurses’ personality factors of 
openness to experience, conscientiousness, and agreeableness, and their “desire for 
innovation” were additional predictors of higher levels of acceptance of pharmacogenetic 
testing (Dodson, 2014, p. e68). 
Summary and Conclusions 
The purpose of Chapter 2 was two-fold. The first purpose was to provide an 
extensive review of the study’s guiding theory: the Rosenstock et al. (1974) HBM. In 
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addition to an explication of the theoretical components of the HBM were discussions of 
the HBM in nursing research and the present study’s application of the HBM. The second 
purpose of the chapter was to provide a comprehensive review of the literature with 
regard to nurses’ perceptions of their own risk for CVD as well as nurses’ knowledge and 
attitudes toward pharmacogenetic testing. The literature review revealed that few studies 
have been conducted with acute-care nurses about their perceived risk for CVD; the 
Jones et al. (2006) study was the most informative study on this topic to date. Studies 
examining nurses’ knowledge and attitudes toward pharmacogenetic testing were, for the 
most part, descriptive studies (e.g., Dodson, 2014, 2015; Haga, O’Daniel, Tindall, Lipkus 
et al., 2012; Haga, O’Daniel, Tindall, Mills et al. 2012; Haga, Tindall, et al., 2012; Van 
Riper et al., 2011) or reviews of the literature (e.g., Dodson, 2011; Godino & Skirton, 
2012; Verschuren et al., 2011). Studies concerning nurses’ attitudes toward 
pharmacogenetic testing (e.g., Dodson, 2011, 2015) highlighted concerns about 
pharmacogenetic testing, such as ethical and financial reimbursement issues, as well as 
advantages, including reduced likelihood of adverse reactions to medications among 
patients. 
The review of the literature uncovered gaps in the literature concerning 
knowledge and attitudes of acute-care nurses regarding pharmacogenetic testing. A 
primary gap found was the lack of studies examining antecedents of perceived risk for 
CVD and knowledge and acceptance of pharmacogenetic testing for CVD. Dodson’s 
(2014) seminal work provided much of the foundation for the present study, as it was the 
only study that examined work-based, demographic, and personality antecedents of 
pharmacogenetic testing knowledge and of attitudes in acute-care nurses. The present 
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study addressed this concerning gap in the literature. The implications of prior research 
on this research have been fully addressed. The study methodology, including the 
research design, sampling issues, study variables and their operational definitions, and 
data collection and analysis procedures are the focus of Chapter 3. 
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Chapter 3: Methodology 
In this quantitative study, using a correlational, cross-sectional design and 
conducted with licensed acute-care nurses in Atlanta, Georgia, I had three goals aligned 
with the HBM (Rosenstock, 1974). The first goal was to determine if nurses’ gender, 
highest level of education, and years of experience significantly related to their perceived 
risk for CVD. The second goal was to determine if nurses’ gender, highest level of 
education, and years of experience significantly related to their knowledge of 
pharmacogenetic testing for CVD. The third and last goal was to determine if a 
significant association arose between nurses’ perceived risk for CVD and their 
acceptance of pharmacogenetic testing for CVD. 
The purpose of this chapter is to provide a summary of the research design and 
methodology. First, I review the research design and rationale in this chapter, and 
continue with an overview of the population and sample, sample size, and sampling 
procedures. I then comprehensively discuss the study methodology, inclusive of the 
instruments used in the study, data-collection procedures, and data analysis. Upon 
completion of the methodology discussion, I provide a summary of instrument reliability 
and validity and outline the ethical procedures of the study. The chapter ends with a 
summary and conclusion section. 
Research Design and Rationale 
The study was quantitative in nature and used a cross-sectional research design. 
The quantitative approach was appropriate for this study, as I statistically analyzed 
numerical data from self-report surveys for hypothesis testing (Stangor, 2014). The 
quantitative approach was guided by the scientific method, with a goal of objectivity. 
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This study was correlational, examining relationships between variables, and cross-
sectional, as data accrued at one point in time (Stangor, 2014). This study was not 
appropriate for a quantitative causal-comparative research design as it focused on 
relationships between independent and dependent variables and does not examine group 
differences on a dependent variable. As this was not a study with intervention and control 
groups, quantitative quasi-experimental and experimental research designs were not 
applicable (aligned with Treiman, 2014). As this was not an experimental quantitative 
study, causality could not be proven (as averred by Kleinbaum, Kupper, Nizam, & 
Rosenberg, 2013). 
Methodology 
Population and Sample 
Study participants, who represented the population of acute-care nurses in the 
United States, were registered acute-care nurses with active licenses working in acute 
hospital settings in Atlanta, Georgia. The sample frame—the group of acute-care nurses 
who had a chance to participate in the study—included all registered acute-care nurses in 
Atlanta, Georgia. As of 2014, the number of licensed acute-care nurses in Georgia was 
155,607 (Stephens, 2015). Approximately 7.5% (n = 11, 670) of these licensed nurses 
worked in acute-care settings in the city of Atlanta (Stephens, 2015). I retrieved work-
contact information for these acute-care nurses from the database of the Georgia Board of 
Nursing with permission of the Board, and I informed all registered acute-care nurses 
who work in acute-care settings in Atlanta of this study and invited them to participate. 
I gave every RN working in an acute-care setting in Atlanta Georgia an equal 
opportunity to participate in this study. However, I did not randomly select acute-care 
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nurses for the study; that is, although the study was open to all acute-care nurses who met 
study criteria, acute-care nurses themselves chose whether to participate in the study. 
Thus, participants comprised a nonprobability purposive sample; being acute-care nurses, 
they were a subset of all acute-care nurses. 
Sample Size 
In accordance with recommendations from Kasiulevičius, Šapoka, and 
Filipavičiūtė (2006) and Charan and Biswas (2013), I conducted an epidemiological 
power analysis for a cross-sectional descriptive study. The power analysis mathematical 
formula for a cross-sectional descriptive study is Z1-α/22 p (1- p)/d2, where Z1-α/22 is the 
normal variate of 1.96 for significance (p) set at < .05, p is the prevalence rate of the 
health issue in the population; and d is “absolute error or precision” as indicated by 
confidence levels, typically set at 95% (or +/- 5% confidence limits; Charan & Biswas, 
2013, p. 122). Power analyses for epidemiological descriptive cross-sectional studies may 
also include a design effect (DE), which is a ratio of the actual variance using the selected 
sampling method to the possible variance using random sampling (Kasiulevičius et al., 
2006). However, DE is a concern when using clustered data, which this study did not use 
(Kasiulevičius et al., 2006). 
I conducted the power analysis using an online epidemiological power analysis 
calculator (http://www.openepi.com/SampleSize/SSPropor.htm). I set the prevalence rate 
to 30%, based on rates of CVD among Caucasian middle-aged women in the United 
States (AHA, 2015; Go et al., 2013; WHF, 2014), the confidence level to 95%, and left 
the DE at the default value of 1.00, as the study data were clustered (Kasiulevičius et al., 
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2006). Results from the power analysis determined that a sample size of N = 228 was 
required for the study. 
Sampling Procedure 
I obtained a purposive sample of N = 228 licensed nurses without a CVD 
diagnosis working in acute-care units at Atlanta metropolitan-area hospitals. With Board 
permission, I retrieved work-contact information of these acute-care nurses from the 
database of the Georgia Board of Nursing. I sent out a study-invitation email to all acute-
care nurses who met study criteria. In this email, I explained the purposes, nature, length, 
and intent of the study; this information was summarized in a study-information letter 
attached to the email. I included a link to the study’s Survey Monkey survey in the text of 
the email and in the study-information letter. The email also contained language that 
reviewed the informed consent procedure and included, as an attachment, the study’s 
informed consent form. The informed consent form stated that participation in the study 
was voluntary and participants could stop answering the survey at any time without 
penalty. I summarized the risks and benefits of participating in the study in the consent 
form, and provided my contact information and the contact information of the 
Institutional Review Board of Walden University. 
The email ended with a request for interested participants to send me an email to 
schedule a phone call to discuss the study in detail, should they want more information 
about the study. Participants had the ability to choose to forgo the phone call and click on 
the Survey Monkey survey link to take the survey online. Before they could answer the 
survey, they first had to read the consent form online and then click “yes” to three 
statements: (a) they understood their rights as a human subject in this research study, 
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(b) their questions or concerns about the study or their role in it were answered; and 
(c) they provided informed consent to participate in the study. If participants clicked “no” 
to any of these statements, they were automatically directed out of the survey link site 
and could not access it again if using the same computer. 
Participants who wished to know more about the study and their role in the study 
could email me to schedule a phone call. I answered any questions from potential 
participants regarding the study during this phone call. Following this call, I again sent 
(through email) the Survey Monkey study link for participants to complete the study 
survey. Participants also had the option to click on the Survey Monkey survey link in the 
original email (and attached document) I sent to them. Participants had 3 weeks to answer 
the survey. The Survey Monkey site that contained the data was accessible only to me, as 
I had registered with Survey Monkey and could only access the data by providing my 
user name and password. 
Instrument and Operationalization of Constructs 
In this section, I first present the instruments used for the study’s independent and 
dependent variables. Following the description of instruments are descriptions on the 
measurement of the independent variables of gender, years of practice, and years of 
education and the study covariates. 
Independent and dependent variables: Perceived risk for cardiovascular 
disease. Perceived risk for CVD was both an independent and dependent variable in this 
study, measured using the Perception of Risk of Heart Disease Scale (PRHDS; Ammouri 
& Neuberger, 2008, see Appendix B). The HBM was the theoretical framework for the 
development of the PRHDS (Ammouri & Neuberger, 2008), as health-risk perceptions 
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were influenced by the individual’s demographics (e.g., age, education level, and gender), 
psychological factors (e.g., self-concept, worldview, and cultural identity), and contextual 
factors (e.g., media reports of CVD risk factors and availability of social resources). The 
PRHDS measures the continuum of perceived risk of heart disease from thinking that one 
has little risk for CVD (e.g., “My lifestyle habits do not put me at risk for heart disease”) 
to dread risk for CVD, or that one’s risk for CVD is definitive (“I feel sure that I will get 
heart disease”; Because the PRHDS measures perceived risk for CVD on a continuum, it 
was treated as an interval-coded scale (Ammouri & Neuberger, 2008). 
The PRHDS has 20 items scored using a Likert-type scale from 1 = strongly 
disagree to 4 = strongly degree (Ammouri & Neuberger, 2008). Of the items, 12 are 
reverse scored and should be recoded before summing items to create the full scale. 
Scores on the PRHDS can range from 20 to 80 points with a higher score denoting higher 
levels of perceived risk for heart disease (Ammouri & Neuberger, 2008). 
A panel of 10 survey development experts assessed the content validity of the 
PRHDS, examining items “for clarity, homogeneity of content, and representativeness of 
the concept domain” (Ammouri & Neuberger, 2008, p. 87). Once the experts gave their 
approval for the survey, Ammouri and Neuberger (2008) confirmed the content validity 
of the PRHDS by conducting a confirmatory factor analysis that showed the one-factor 
PRHDS explained 53% of the variance. There are significant associations between the 
PRHDS and scale of health responsibility, physical activity, spiritual growth, and stress 
management, confirmed criterion-related validity of the PRHDS with rs ranging from .21 
to .39, p < .01. The inter-item reliability for the PRHDS had a Cronbach’s alpha of .80 
and the 2-week test–retest reliability is .69 (Ammouri & Neuberger, 2008). 
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Dependent variable: Knowledge of pharmacogenetic for cardiovascular 
disease. I assessed knowledge of pharmacogenetic testing for CVD, which was a 
dependent variable in this study, using the Pharmacogenomics Knowledge Scale (PKS; 
Bannur et al., 2014, see Appendix C). Bannur et al. (2014) developed the PKS to inform 
the professional practice of CVD pharmacogenetic testing in healthcare settings, arguing 
that healthcare providers must demonstrate “the skill to translate patient’s genetic history 
for optimum drug therapy” to prevent or delay CVD (p. 40). The ratio-coded PKS 
comprised five items scored as 1 = true and 0 = false; three items are true and two items 
are false. An example item is “Pharmacogenetic testing is currently available for most 
heart disease medications” (scored as a false item). The total PKS scale score is a sum of 
the number of correct items divided by five to obtain a percentage score, which can range 
from 0% to 100% (Bannur et al., 2014). 
The PKS went through a rigorous two-panel review process to determine its 
content validity. Five researchers specializing in the field of pharmacogenetic testing sat 
on the first panel, and the second panel included 10 pharmacists and physicians (Bannur 
et al., 2014). The two panels confirmed the content validity of the PKS. Bannur et al. 
(2014) validated the PKS in a study conducted with 503 healthcare professionals. 
Significant relationships between pharmacogenetic testing knowledge and genetics 
knowledge (at r = .27, p < .01) provided support for criterion-related validity. Statistical 
results supported the discriminant validity of the PKS, showing significantly higher mean 
scores among pharmacists and physicians having more years of practice than those 
having fewer years of practice, χ² (4, N = 1,500) = 78.79, p < .001, and pharmacists and 
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physicians working in urban healthcare settings versus rural healthcare settings, χ² (2, 
N = 1,500) = 7.48, p = .024 (Bannur et al., 2014). The PKS scores dichotomously. 
Dependent variable: Acceptance of pharmacogenetic testing for 
cardiovascular disease. I used the Attitudes Toward Pharmacogenomics Scale (APS; 
Bannur et al., 2014) to measure acceptance of pharmacogenetic testing for CVD, which 
was a dependent variable in this study. Bannur et al. (2014) developed the APS to address 
the lack of awareness of CVD pharmacogenetic testing among healthcare providers. The 
APS is a Likert-coded scale comprising eight questions that assess the degree to which 
healthcare providers feel comfortable with and accept pharmacogenetic testing for CVD 
for their patients. An example item is, “How comfortable would you be having genetic 
information incorporated into the determination of your patient’s initial warfarin dose?” 
The response coding for APS items range from 1 = very uncomfortable to 5 = very 
comfortable. Summing the scores from each of the eight items provides a total APS 
score; scale scores can range from 8 to 40 with a higher score denoting higher levels of 
comfort/acceptance (Bannur et al., 2014). 
The APS went through a rigorous two-panel review process to determine its 
content validity. Five researchers specializing in the field of pharmacogenetic testing sat 
on the first panel, and the second panel included 10 pharmacists and physicians (Bannur 
et al., 2014). These two panel reviews confirmed the content validity of the APS (Bannur 
et al., 2014). A study conducted with 1,500 healthcare professionals validated the APS. 
Significant relationships between acceptance of pharmacogenetic testing and genetics 
knowledge (r = .17, p < .05) provided support for criterion-related validity. Findings 
showing significantly higher mean scores among cardiologists, compared to other types 
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of physicians, F(2, 500) = 7.80, p = .001, and healthcare providers working at pharmacies 
or medical schools, compared to healthcare providers working in other settings (e.g., 
public/private hospital, private practice), F(2, 500) = 2.71, p = .041 supported the 
discriminant validity of the APS. The inter-item reliability of the APS is .76 (Bannur et 
al., 2014). 
Independent variable: Gender. I measured the independent variable of gender 
with a dichotomously coded question: “What is your gender?” The response coding was 
0 = female and 1 = male. 
Independent variable: Years of education. I measured the independent variable 
of years of education with an ordinal-coded item: “What is the highest educational degree 
you have completed?” Responses scored were 1 = Associates’ degree, 2 = Bachelors’ 
degree, 3 = Master’s degree, and 4 = Doctorate degree. 
Independent variable: Years of practice. I measured the independent variable 
of years of practice with an open-ended question: “How long have you been in your 
current position?” The question aimed to obtain information on years of practice, a ratio 
variable. 
Covariate: Health factors related to estrogen. In the survey, I asked 
participants if they (a) had a hysterectomy, (b) were postmenopausal, (c) were on 
hormone-replacement therapy, or (d) took birth-control pills. If participants answered 
“yes” to one or more of these items, they were categorized as 1 = have health factor 
related to estrogen. If participants answered “no” to all of these questions, they were 
categorized as 0 = have no health factors related to estrogen. 
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Covariate: Medication-related cardiovascular disease risk. I asked acute-care 
nurses if they took any medications(s) that can influence CVD risk; that is, medications 
used for other health conditions but that increased CVD risk (e.g., birth control, 
prednisone) or decreased CVD risk (e.g., diuretics). I provided participants a list of 
medications that had associated CVD risk and asked them to select the medications they 
were currently prescribed. I categorized participants who did take such medication(s) into 
the 1 = have medication-related CVD risk group, whereas participants who did not take 
such medication(s) were categorized into the 0 = do not have medication-related CVD 
risk group. 
Data-Analysis Plan 
I transferred the Survey Monkey data file directly into an SPSS 22.0 data file, 
kept on a jump drive. Once I downloaded the data into an SPSS data file, I reviewed the 
data set and corrected for entry mistakes, missing data, and outliers. If a case was missing 
>= 50% or if a case had >= 25% of data missing not at random (MNAR), it was removed 
from the data set (aligned with Stangor, 2014). I determined univariate outliers using the 
SPSS outlier function, and winsorized identified outliers (i.e., replaced them with the next 
lowest or highest value. I detected multivariate outliers with the SPSS Mahalanobis 
distance function. I calculated the inter-item reliability for pharmacogenetic testing 
knowledge and acceptance scales with Cronbach’s alpha; an acceptable Cronbach’s alpha 
is >= .70 (in line with Stangor, 2014). I computed study scales. 
Prior to performing the regression analyses for hypothesis testing, I conducted 
descriptive and preliminary inferential statistical analyses, reporting frequencies and 
percentages for the demographic variables and covariates and the means, standard 
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deviations, and minimum and maximum scores for the study scales (i.e., PRHDS, PKS, 
and APS). I conducted specific statistical tests to determine and address violations of 
assumptions for regression analyses (as suggested by Stangor, 2014). I determined the 
assumption of normality in the distribution of scale scores by calculating scale skewness 
scores (i.e., skewness value divided by skewness standard error). A skewness value that 
is < 2.00 indicates that the multivariate normality assumptions have been met. 
Homoscedasticity is an assumption that pertains to the equality of residual errors (i.e., 
errors are constant), tested by plotting residuals using scatterplots. If the data points 
display an equivalent distribution above and below the horizontal line, this assumption 
has been met (Stangor, 2014). Multicollinearity, another assumption for linear regression 
analyses, refers to a very high correlation among independent variables to the extent that 
they are measuring the same construct. Variance inflation factors (VIFs) for each 
independent variable association determine multicollinearity. This assumption is met if 
VIFs are < 4.00 (Stangor, 2014). 
For this dissertation, I proposed seven research questions. For Research Questions 
1 through 3, I conducted one HMLR. I entered the covariate of take medication that 
affected CVD risk in the first model (step) of the HMLR, as it significantly related to the 
dependent variable of perceived risk for CVD. I entered the independent variables of 
gender, years of education, and years of experience together in the second model (step) of 
the HMLR. Perceived risk for CVD was the dependent variable for these first three 
research questions. 
For Questions 4 through 6, I conducted a MLR; I did not include the two variables 
of take medication that affects CVD and estrogen-related health conditions in analyses as 
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they did not significantly correlate with the dependent variable of knowledge of 
pharmacogenetic testing for CVD. I entered the independent variables of gender, years of 
education, and years of experience collectively in the first and only model (step) of the 
MLR. The dependent variable for the fourth through sixth research questions was 
knowledge of pharmacogenetic testing for CVD. 
I conducted an HLR for the seventh and last research question. Knowledge of 
pharmacogenetic testing for CVD significantly aligned with acceptance of 
pharmacogenetic testing for CVD and thus, I entered it as a covariate in the first model 
(step) of the HLR, followed by the independent variable of perceived risk for CVD in the 
second model (step) of the HLR. Perceived acceptance toward pharmacogenetic testing 
for CVD was the dependent variable for the seventh and last research question. 
The decision to enter independent variables collectively versus singly would have 
required six HMLRs/MLRs, which would have decreased the power of the study, 
resulting in an increased likelihood of committing a Type I error (i.e., rejecting the null 
hypothesis when it should have been retained). Entering the independent variables 
together on one model (step) of the HMLR/MLR increased the statistical power of the 
analysis. Further, these analyses allowed determination of which of the three independent 
variables were most influential and also informed me “about the structure by which 
multiple predictors simultaneously” related to the dependent variable (Stangor, 2014, 
p. 341). 
I determined statistical significance of the HMLR models by a significance level 
of p < .05 (as suggested by Kleinbaum et al., 2013). Results included the overall F- and 
p-values for the two models, and determined the model effect size by the model R2 
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(Kleinbaum et al., 2013). Results for the individual predictors included the predictors’ 
standardized beta weights (β) and p-values (Kleinbaum et al., 2013). 
Instrument Reliability and Validity 
Instrument reliability refers to the degree to which an assessment tool produces 
stable and consistent results across times (test–retest reliability), observers (interrater 
reliability), and instrument items (inter-item reliability; Stangor, 2014). Conducting test–
retest reliability was beyond the scope of this study, and the uses of self-report 
instruments precluded the need to conduct interrater reliability (according to Stangor, 
2014). The instruments used in this study demonstrated sound inter-item reliability. 
Nonetheless, I calculated the inter-item reliability coefficients by computing Cronbach’s 
alphas for the study instruments. Cronbach’s alphas that are .70 or higher are acceptable 
and Cronbach’s alphas that are greater than .90 are deemed excellent for inter-item 
reliability (Stangor, 2014). 
Instrument validity is the degree to which a test measures what it is purported to 
measure (Stangor, 2014). Of the different types of instrument validity, content validity 
concerns the degree to which the items in an instrument measure a desired construct. 
Expert panels often determine content validity of an instrument when considering 
nonstatistical approaches, and exploratory of confirmatory factor analyses when using 
statistical approaches. Discriminant validity refers to the ability of an instrument to detect 
and measure differences between two or more groups that should demonstrate differences 
(Stangor, 2014). For example, as stated previously, the discriminant validity of the PKS 
was demonstrated by significantly higher mean scores between pharmacists and 
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physicians who had more years of practice than their counterparts who had fewer years of 
practice (Bannur et al., 2014). 
Criterion-related validity refers to the degree to which a scale score correlates 
with a score on an instrument that measures the same or similar construct (Stangor, 2014). 
As noted previously, the APS (Bannur et al., 2014) demonstrated criterion-related 
validity by significantly correlating with a test of genetics knowledge (r = .17, p < .05; 
Bannur et al., 2014). Psychometric studies confirmed the validity of the study scales, 
leaving no need to conduct validity testing of instruments that have already been shown 
to be valid. 
Study Validity 
Three types of validity in quantitative research studies pertain to study limitations 
in research methodology and design: (a) internal validity, or the degree to which it can be 
stated that the observed effects on the dependent variable(s) is due to independent 
variables and not to unmeasured confounding variables; (b) external validity, or the 
ability to generalize study results to the population or other samples, settings, and times; 
and (c) construct validity, or how well a study instrument operationally captures the 
constructs under study (Jackson, 2015). Quantitative studies have threats to internal, 
external, and construct validity, but these differ according to the type of quantitative 
research design employed in the study (Jackson, 2015). 
Threats to Internal Validity 
Threats to internal validity are participant or study factors that compromise the 
ability to state that dependent variable effects were the result of the independent variable 
(Jackson, 2015). Threats exist to the internal validity for associational quantitative studies, 
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the primary ones being (a) confound bias, (b) self-selection bias, (c) social-desirability-
response bias, and (d) reverse causation (Jackson, 2015). Confound bias, the “third 
variable problem,” concerns the inability to conclude that dependent-variable effects are a 
result of the independent variable, due to an unmeasured extraneous variable that 
significantly aligned with the independent and dependent variables (Armistead, 2014, 
p. 2). Covariate analysis is a recommended technique to control for confounds bias 
(Armistead, 2014). In the present study, two covariates were health factors related to 
estrogen and medication-related CVD risk. 
Self-selection or volunteer bias occurs in studies that rely on a convenience 
sample rather than on random selection of study participants; participants who volunteer 
for a study tend to differ in “relevant clinical characteristics” from those who do not 
participate in a study (Tripepi, Jager, Dekker, & Zoccali, 2010, p. 98). Examinations of 
the self-selection bias in healthcare research has shown that study volunteers tend more 
likely to be women and have high levels of education (Tripepi et al., 2010). As these two 
factors were variables in this study, I considered this bias when analyzing, interpreting, 
and reporting study data. 
Social-desirability-response bias, the tendency of study participants to provide 
answers to survey items that are socially acceptable irrespective of the truth, is an issue in 
associational studies using self-report instruments (Stangor, 2014). Social-desirability-
response bias is more likely to occur when researchers ask participants sensitive 
questions, such as questions about their weight, health and mental health problems, and 
attitudes toward coworkers and supervisors (Chung & Monroe, 2003; Edmonds & 
Kennedy, 2012). I considered the study variables of gender, level of education, and years 
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of practice to be unthreatening as they are questions often asked in daily settings. It was 
unlikely that nurses found the knowledge and attitudes toward pharmacogenetic testing 
for CVD to be threatening or sensitive, as these questions pertained more to their skill set 
than to personal aspects of their life. Of all study variables, perceived risk for CVD may 
have been the variable that was most impacted by this bias: participants may have felt 
that, as nurses, they should not be at risk for CVD and may have downplayed their actual 
risk. Some evidence exists that social-desirability bias is less likely to occur in studies 
that use online-survey formats due to the perceived social distance between study 
participants and researcher (Chung & Monroe, 2003; Stangor, 2014). The informed-
consent process, wherein I informed participants that their survey responses were 
confidential and anonymous, may have also reduced social-desirability bias (as suggested 
by Stangor, 2014). 
A final threat to internal validity for correlational studies is reverse causation, 
which concerns the inability to determine temporal precedence of variables (Jackson, 
2015). Genders, level of education, and length or practice were, in this study, immutable 
variables that could not be changed by or result from a dependent variable. The only 
research question that reverses causation might have influenced was the seventh question 
pertaining to perceived risk for CVD and attitudes toward pharmacogenetic testing: 
participants’ attitude toward pharmacogenetic testing may have influenced their 
perceived risk for CVD. However, as these variables measured disparate constructs, the 
risk of reverse causation diminished. The use of HMLR analyses rather than bivariate 
correlation analysis further minimized this threat (Jackson, 2015). 
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Threats to External Validity 
External validity pertains to the ability to generalize study results beyond the 
study sample to the population (or other samples), to other points in time, and to other 
settings (Jackson, 2015). The external validity of a study depends greatly on the degree to 
which study participants represent the population. Convenience sampling reduced the 
external validity of the present study, and generalizations of results from this study are 
limited (aligned with Jackson, 2015). Results from this study cannot be generalized to 
acute-care nurses who work in outpatient settings, critical care, primary care, public 
health departments, doctor’s offices, or other nonhospital clinical milieus. Furthermore, 
results from this study cannot be generalized to registered acute-care nurses working in 
other locations in the United States, nurse assistants, or acute-care nurses who have CVD. 
Threats to Construct Validity 
Construct validity pertains to the degree to which an instrument measures the 
construct it is intended to measure (Houghton, Hunter, & Meskell, 2012). One threat to 
construct validity that was a concern in this study was the inadequate explication of 
constructs, which concerned the incorrect or inexact operationalization of study 
constructs. The measures used in this study have sound construct validity, minimizing the 
threat of inadequate explication of constructs. Another threat to construct validity is 
monomethod bias, which is the use of a single measure of a construct in a study 
(Houghton et al., 2012). This study was limited by this bias, and conclusions from results 
are legitimate only in relation to the specific operationalization of the variables of 
perceived risk for CVD and knowledge and acceptance of pharmacogenetic testing for 
CVD. 
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Ethical Considerations 
Ethics should be the foundation of any research study, but are especially 
important in a study that involves the use of human subjects (Stangor, 2014; National 
Institutes of Health Approval No. 894379, see Appendix D). I followed the ethical 
procedures outlined by The Institutional Review Board of Walden University (approval 
number is 03-11-16-0172642 and it expires March 10, 2017.), which had ultimate 
approval of this research project prior to data collection, to ensure participants were fully 
protected. Participants in this study had to review and agree to informed consent, 
acknowledge they understood their rights as human subjects in research studies, and 
confirm that any questions they had were answered. They were required to click “yes” to 
denote their agreement to statements that (a) they gave consent to participate in the study; 
(b) they understood their rights as human subjects in research; and (c) if they had any 
questions, these were answered to their satisfaction. “No” responses resulted in a 
termination of the survey, which participants could no longer access. 
Other study procedures provided additional ethical assurances. Due to the blind 
recruitment and participation process, I had no knowledge as to who completed the study. 
The data were confidential and anonymous. I treated the study data and material in an 
ethical manner. I was the only person with access to the Survey Monkey survey link, 
survey site, and data. Once the study was completed, I deleted the Survey Monkey files 
from the Survey Monkey server. I kept data on a jump drive (not a computer hard drive), 
stored in a secured and locked file cabinet in my home office. Study paper documents and 
the jump drive will be destroyed after 3 years. 
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Summary 
Describing acute-care nurses’ CVD risk-factor awareness and knowledge of 
pharmacogenetic testing is quite crucial in developing interventions for CVD risk among 
acute-care nurses. Because acute-care nurses are at the forefront of health promotion and 
disease prevention, it is very important for them to observe healthy behaviors and to 
educate their patients to perceive the severity of CVD risk. I wanted to know if acute-care 
nurses’ CVD awareness significantly impacted healthy behavior such as smoking 
cessation, healthy eating habits, regular physical activity, maintaining a healthy weight, 
and blood pressure and cholesterol screening habits. In Chapter 4, I discuss the study 
findings. 
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Chapter 4: Results 
Researchers have documented a paradox between actual risk and perceived risk 
for CVD among nurses: nurses do not perceive themselves as being at risk for CVD 
despite often having numerous risk factors for this disease (Hörnsten et al., 2014; Jones et 
al., 2006). This lack of congruence may not only impair the health and work behaviors of 
nurses, but may also influence their cognitions and attitudes toward CVD-related 
practices, such as pharmacogenetic testing for CVD (Chan & Perry, 2012). The 
knowledge base among nurses of pharmacogenetic testing, as well as the acceptance of 
such testing, is furthermore limited as a result of the newness of such testing and the 
controversy that surrounds it such as the confidentiality of the test results (Johnson & 
Cavallari, 2013; Verschuren et al., 2011). Nurses’ lack of perceived risk of CVD, lack of 
knowledge of pharmacogenetic testing for CVD, and limited acceptance of 
pharmacogenetic testing for CVD may influence their nursing practices, interactions with 
patients, and the types of information and knowledge they share with patients (Dodson, 
2011, 2015; Moen & Lamba, 2012). Ultimately, patients’ health and well-being is at 
stake (Moen & Lamba, 2012). 
The purposes of this study were three-fold. The first purpose was to examine if 
nurses’ highest level of education, years working as RNs, and gender significantly 
influenced their perceived degree of risk for CVD. The second purpose was to examine if 
these three factors significantly influenced their reported level of knowledge of 
pharmacogenetic testing for CVD. The third and final purpose of this study was to 
determine if nurses’ perceived degree of risk for CVD significantly influenced their 
reported level of acceptance of pharmacogenetic testing for CVD. 
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The purpose of this chapter is to present and discuss the results of regression 
analyses (HMLR, MLR, and HLR) conducted for hypothesis testing. The chapter opens 
with a review of the data-collection procedures, including the time frame in which the 
data collection occurred and the representativeness of the study sample. This section 
provides substantial attention to response rates. The chapter continues with a presentation 
of the descriptive information of study-participant variables, including demographic and 
health factors. I then discuss the results of the study, beginning with a review of study 
variables including scale construction, descriptive statistics, missing data and outliers, 
and how these were addressed. The results section also includes the testing for covariates 
and the testing of assumptions for linear regression models. I devote the last sections of 
the chapter to hypothesis testing, with results from the linear regression models assessed 
in relation to the null hypotheses of the research questions. A summary concludes the 
chapter. 
Data Collection 
I distributed a total of 1,545 surveys to acute-care nurses in the state of Georgia 
through email from March 1, 2016 to April 30, 2016. Of 1,545 surveys sent, 344 (23.8%) 
nurses responded to the surveys. I then removed cases if participants (a) did not provide 
informed consent (n = 26, 7.6%), (b) did not meet study criteria (n = 46, 13.4%), or (c) 
did not answer any of the survey questions (n = 34, 9.9%). This resulted in a sample of N 
= 238 nurses who provided informed consent and met study criteria, 69.2% of those who 
clicked on the Survey Monkey survey link. 
I reviewed the dataset for MNAR data and missing completely at random data. 
Eight cases had MNAR data. Of these eight, three (37.5%) did not provide answers to the 
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PKS (Bannur et al., 2014) and the PRHDS (Ammouri & Neuberger, 2008) and five did 
not answer the PRHDS or the questions regarding taking medication to control blood 
pressure. As the data were MNAR, I removed these cases from analyses, lowering the 
study sample size to 230, the final sample, 66.9% of those who clicked on the Survey 
Monkey survey link. The remaining missing data were missing completely at random, 
with a total of 14 missing data points across a total of 12 items (eight PRHDS items and 
four PKS items). I used mean imputation to replace missing data. 
Descriptive Statistics: Participants 
Two hundred and thirty nurses participated in this study. Table 1 presents 
demographic and work information from participants. Of these 230 participants, 37 
(16.1%) were male and 193 (83.9%) were female. A chi-square (χ²) goodness-of-fit test 
determined that this study sample had a significantly higher percentage of male nurses 
compared to the population of nurses, χ² (1) = 33.58, p < .001. Almost half of participants 
(n = 108, 47.0%) had bachelor’s degrees, and almost a quarter of participants (n = 56, 
24.3%) had bachelor’s degrees plus additional training/certification. Of participants, 35 
(15.2%) had associate’s degrees, 13 (5.7%) had master’s degrees, and 16 had master’s 
degrees plus additional training/certification. Participants indicated a broad range of years 
worked as a RN, from less than 1 year to more than 30 years. The majority (n = 132, 
57.4%) of participants worked as RNs between 1 and 10 years. 
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Table 1 
Descriptive Statistics: Demographics of Study Participants (N = 230) 
 Frequency Percentage 
Gender   
Male 37 16.1 
Female 193 83.9 
Highest level of education   
Associate’s 37 16.1 
Bachelor’s 108 47.0 
Bachelor’s plus additional training/certification 56 24.2 
Master’s 13 5.7 
Master’s plus additional training/certification 16 7.0 
Years worked as a registered nurse   
Less than 1 year 13 5.7 
1–3 years 40 17.4 
4–6 years 52 22.6 
7–10 years 40 17.4 
11–14 years 17 7.4 
15–19 years 17 7.4 
20–24 years 16 7.0 
25–30 years 24 10.4 
More than 30 years 11 4.7 
 
Descriptive Statistics: Covariates 
I asked participants if they had any disorders or diseases related to estrogen levels 
and if they took medication that is known to affect blood pressure. Descriptive 
information on these variables appears in Table 2. The majority of female participants 
(n = 168, 81.0%) reported no estrogen-related disorders, diseases, or events, and 48 
(20.9%) female participants (100% female) reported one estrogen-related disorder, 
disease, or event. Of those 48 participants, seven (14.6%) reported having polycystic 
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ovarian syndrome, six (12.5%) reported infertility, and three (6.3%) reported having 
endometriosis. In addition, 22 (45.8%) participants reported the event of post menopause 
whereas 10 (20.8%) reported the event of having a hysterectomy. Of 100% female 
participants, 14 (6.1%) reported two estrogen-related disorders or diseases: specifically, 
hysterectomy and post menopause. 
I asked participants if they took medication that could affect their blood pressure. 
The majority of participants (n = 168, 73.0%) reported not taking such medications and 
40 (17.4%) reported taking one medication. Of those 40 participants, 11 (27.5%) reported 
taking nonsteroidal anti-inflammatories, seven (17.5%) reported taking estradiol/birth-
control pills, six (15.0%) reported taking statins, four (10.0%) reported taking synthetic 
thyroid-replacement medication, three (7.5%) reported taking diuretics, three (7.5%) 
reported taking calcium channel-blocking agents, three (7.5%) reported taking synthetic 
estrogen-replacement medication, two (5.0%) reported using an asthma inhaler, and one 
(2.5%) reported taking proton-pump inhibitors. Almost three quarters of participants 
reported taking no medications that affect blood pressure. 
Descriptive Statistics: Study Scales 
This study had three primary scales: (a) the PRHDS (Ammouri & Neuberger, 
2008), used in this study as an independent and dependent variable, assessed the degree 
to which one perceives oneself to be at risk for getting any type of CVD; (b) the PKS 
(Bannur et al., 2014), a dependent variable that measured the degree of knowledge about 
pharmacogenetic testing for CVD; and (c) the APS (Bannur et al., 2014), a dependent 
variable that measured the level of acceptance toward pharmacogenetic testing for CVD. 
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Table 2 
Descriptive Statistics: Study Participants’ Number of Estrogen-Related Diseases, 
Disorders, or Events, and Number of Medications Taken that Affect Blood Pressure  
 Frequency Percentage 
Number of Estrogen-Related Diseases or Disorders (Female Only, n = 193) 
0 131 67.9 
1 48 24.9 
2 14 7.2 
Number of Medications Taken That Affect Blood Pressure (All Participants, N = 230) 
0 168 73.0 
1 40 17.4 
2 15 6.6 
3 5 2.2 
4 1 0.4 
5 1 0.4 
 
Scale Development and Computations 
The 20-item PRHDS measures the degree to which one perceives oneself at risk 
for any type of CVD. The PRHDS, on which 12 of the 20 items are reverse-scored, 
comprises three subscales. The 7-item Unknown Risk subscale comprises items that 
assess external locus of control aspects of risk for CVD; an example is “No matter what I 
do, if I am going to get heart disease, I will get it.” 
The computation of the PRHDS was initiated by recoding the 12 reverse-scored 
items to correspond to the scoring of the other 8 items. I then examined the scale inter-
item reliability by computing the Cronbach’s alpha for the total PRHDS scale. The 
Cronbach’s alpha was an unacceptable .60 for the overall PRHDS. A review of 
Cronbach’s alpha values if certain items were deleted from the scale showed that the 
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seven Unknown Risk items were the cause of the low Cronbach’s alpha. When I removed 
these seven items, the Cronbach’s alpha was a very acceptable .77. This study thus used a 
13-item PRHDS, comprised of the two subscales of Dread Risk and Risk. 
I scored the 5-item PKS, used to measure knowledge of pharmacogenetic testing 
for CVD, as though it was a test or examination, using a scale from 0% to 100%. Due to 
the true/false scoring of the PKS, I could not compute a Cronbach’s alpha. The APS 
measured acceptance of pharmacogenetic testing for CVD. Outlier boxplots and unusual 
case-function testing revealed that the APS had two outliers, both of which were 
extremely low scores of 11. I winsorized these two scores, replacing them with the next 
lowest score, which was 15. Outlier boxplots and unusual case-function testing revealed 
no univariate outliers for the PRHDS and PKS. The computation of the Mahalanobis 
distances uncovered no multivariate outliers. 
The descriptive statistics for these three scales appear in Table 3. Information 
included in Table 3 includes the zskewness value of the scale. This is an indicator of 
normality: zskewness values less than +/-1.96 indicate relative normality (Kim, 2013). I 
report Cronbach’s alphas (αs) as indicators of inter-item reliability for the APS and 
PRHDS scales. A Cronbach’s α greater than or equal .70 indicates acceptable inter-item 
reliability (Garson, 2012). 
The mean score on the PRHDS was 26.30 (SD = 4.97), with PRHDS scores 
ranging from 13.00 to 40.00 points. The mean was relatively low, and the range of scores 
did not extend to the highest possible score of 52. These descriptive statistics suggested 
participants perceived they had a relatively low risk for developing CVD. PRHDS 
nonetheless had a normal distribution of scale scores, as indicated by a zskewness value 
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of -1.65. The Cronbach’s α of the PRHDS was good, with a Cronbach’s α of .77. The 
mean score on the PKS was 68%, equivalent to a D+, and scores on the PKS ranged from 
0% to 100%. The zskewness value of -1.55 indicated that the PKS had relative normality. 
The mean score of the APS was 31.77 (SD = 5.13), and scores on the APS ranged from 
15.00 to 45.00 points. The APS had an acceptable zskewness value of -1.77, indicating 
relative normality and the inter-item reliability of the APS was sound, with a Cronbach’s 
α of .75. 
Table 3 
Descriptive Statistics: Attitude Toward Pharmacogenomics Scale, Pharmacogenomics 
Knowledge Scale, and Perceived Risk for Heart Disease Scale (N = 230) 
 M SD Min Max zskewness Alpha 
Perceived Risk for Heart Disease 
Scale (PRHDS) 
26.30 4.97 13.00 40.00 -1.65 .77 
Pharmacogenomics Knowledge 
Scale for CVD (PKS) 
0.68 0.19 0.00 1.00 -1.55 N/A 
Attitudes toward 
Pharmacogenomics for CVD 
Scale (APS) 
31.77 5.13 15.00 45.00 -1.77 .75 
Note. M = mean, SD = standard deviation, Min = minimum score, Max = maximum score. zskewness = 
skewness/standard error of skewness; and α = Cronbach’s alpha; The possible range of scores on the 
PRHDS is 13.00–52.00 points. The possible range of scores on the PKS is 0%–100%. The possible range 
of scores on the APS is 9.00–45.00 points. 
Testing of Covariates 
I included the questions about estrogen-related diseases, disorders, and events, 
and the medications taken that could affect blood pressure in the study survey as potential 
covariates; that is, I thought they would significantly relate to the dependent variables of 
(a) perception of risk for heart disease, as measured by the PRHDS; (b) pharmacogenetic 
testing knowledge, as measured by the PKS, and (c) acceptance of pharmacogenetic 
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testing, as measured by the APS. I summed the total scores of the estrogen-related 
diseases, disorders, and event items and the medication that could affect blood pressure 
items, dichotomized so that 1 = presence of disease, disorder, or event or take at least one 
medication and 0 = absence of disease, disorder, or event and do not take any medication. 
I then conducted Spearman’s rho, with results presented in Table 4. 
As seen on Table 4, although the variable of having estrogen-related diseases, 
disorders, or events did not significantly associate with perceptions of risk for CVD, the 
variable of take medications that could affect blood pressure did significantly associate 
with this dependent variable, rs(230) = .14, p = .038. I included take medication that 
could affect blood-pressure in the analyses to test Research Questions 1 through 3. 
Neither presence/absence of estrogen-related diseases, disorders, or events, or currently 
taking medication that could affect blood pressure significantly aligned with acceptance 
of pharmacogenetic testing or with knowledge of pharmacogenetic testing. Thus, I 
included neither item as a covariate in the analyses to test Research Questions 4 through 
7. 
I conducted one Pearson bivariate correlation between pharmacogenetic testing 
knowledge and acceptance of pharmacogenetic testing. The result from the Pearson 
bivariate correlation showed significance, r (230) = .14, p = .043, indicating that, as 
knowledge of pharmacogenetic testing increased, so did acceptance of such testing. I 
entered the variable of pharmacogenetic-testing knowledge as a covariate in the analyses 
to test Research Question 8. 
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Table 4 
Spearman’s Rho Correlations: Estrogen-Related Diseases, Disorders, or Events, and 
Currently Take Medications That Could Affect Blood Pressure and Attitude Toward 
Pharmacogenomics Scale and Pharmacogenomics Knowledge Scale (N = 230) 
 
Perception of Risk for 
Heart Disease Scale 
(PRHDS) 
Attitudes toward 
Pharmacogenomics 
Scale for CVD (APS) 
Pharmacogenomics 
Knowledge for CVD 
Scale (PKS) 
Have estrogen-related 
disease, disorder, or event 
(Y/N) 
.08 -.03 -.12 
Take medications that could 
affect blood pressure (Y/N) 
.14* -.03 -.07 
Note. CVD = cardiovascular disease; *p < .05 
Testing of Assumptions for Linear Regression Models 
HMLR, conducted to address Research Questions 1 through 3, MLR, conducted 
to address Research Questions 4 through 7, and HLR, conducted to address the eighth 
research question all had the same assumptions: (a) normality of continuously-coded 
independent and dependent variables; (b) lack of multicollinearity between independent 
variables; (c) independence of errors in linear regression/HLR results; and 
(d) homoscedasticity of errors in linear regression/HLR results (Garson, 2012). Normality 
was already addressed by computing zskewness values, and the three study variables had 
zskewness under 1.96, signifying the normality assumption was met. The three remaining 
assumptions were tested, with results presented in the following sections. 
Assumption of Lack of Multicollinearity 
I assessed multicollinearity, or high correspondence between independent 
variables so they essentially are measuring the same construct (Garson, 2012; Kleinbaum 
et al., 2013), by computing Spearman’s rho correlations and VIFs among the independent 
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variables of highest level of education, years of working as a RN, and gender. A 
Spearman’s rho correlation of rs >= .90, p < .001 and a VIF > 10.00 indicate 
multicollinearity (Garson, 2012; Kleinbaum et al., 2013). 
I did not expect these demographic and work variables to display multicollinearity, 
and results from the Spearman’s rho correlation analyses and the computing of VIFs 
supported this expectation. Gender significantly correlated with years worked as a RN, 
rs(230) = .20, p = .003: being female significantly aligns with increased number of years 
worked as an RN. The correlation coefficient of rs = .20 was well below the critical 
coefficient value of rs = .90. All VIFs were considerably below the critical value of 10.00. 
Multicollinearity was not evident in these findings. The assumption of lack of 
multicollinearity was met (see Table 5). 
Table 5 
Testing for Multicollinearity: Spearman’s Rho Correlation Coefficients and Variance 
Inflation Factors (N = 230) 
 
Highest level of 
education 
Years as a registered 
nurse Gender 
Highest level of education — 1.00 1.04 
Years as registered nurse .06 — 1.00 
Gender -.01 .20* — 
Note. *p < .05. Spearman’s rho correlations are below the diagonal and variance inflation factors are above 
the diagonal. 
Assumption of Independence of Errors 
I tested the assumption of independence of errors, or the lack of autocorrelation 
among errors, by calculating Durbin-Watson values for each HMLR/MLR/HLR model. 
Durbin-Watson values between 1.00 and 3.00 indicated this assumption was met (Garson, 
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2012; Kleinbaum et al., 2013). The Durbin-Watson values for each model of the three 
regression analyses conducted appear in Table 6. As can be seen in Table 6, all Durbin-
Watson values fell between 1.00 and 3.00, signifying that the assumption of 
independence of errors was met for all models in the regression analyses. 
Table 6 
Testing for Independence of Errors: Durbin–Watson Values for Each Regression 
Analysis for Hypothesis Testing (N = 230) 
 HMLR for RQs 1–3 MLR for RQs 4–7 HLR for RQ 8 
Durbin–Watson Value 1.86 2.04 1.94 
Note. HMLR = hierarchical multiple linear regression; RQ = research question; MLR = multiple linear 
regression; HLR = hierarchical linear regression. 
Assumption of Homoscedasticity of Errors 
I tested the assumption of homoscedasticity of errors, or the constancy of errors in 
linear regression analyses, by plotting residuals using scatterplots. If the data points 
displays an equivalent distribution above and below the horizontal line at zero, this 
assumption has been met (Garson, 2012; Kleinbaum et al., 2013). I computed three 
scatterplots for each of the three linear regression analyses. As shown in Figures 3, 4, and 
5, the distribution of error data points was equivalent above and below the horizontal zero 
for each scatterplot. The assumption of homoscedasticity of errors was met for each 
linear regression model. 
Hypothesis Testing 
This study posed seven research questions. As stated in Chapter 3, one MLR 
addressed Research Questions 1 through 3 as were Research Questions 4 through 6. An 
HLR addressed the seventh and last research question. This section of the chapter is 
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structured to present the results from the MLRs, followed by a presentation of results for 
each research question, with reference to whether the results supported the rejection or 
acceptance of the null hypothesis. 
 
Figure 2. Scatterplot of residuals: Medication that could affect blood pressure, highest 
level of education, years worked as a registered nurse, and gender predicting perceived 
risk for CVD. 
 
 
Figure 3. Scatterplot of residuals: Highest level of education, years worked as registered 
nurse, and gender predicting knowledge of pharmacogenetic testing. 
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Figure 4. Scatterplot of residuals: Knowledge of pharmacogenetic testing and perceived 
risk for CVD predicting acceptance of pharmacogenetic testing. 
 
Hierarchical Multiple Linear Regression 1: Research Questions 1–3 
The first through third research questions examined if highest level of education, 
years worked as a RN and gender were significant predictors of perceived risk for CVD. I 
entered take medication that could affect blood pressure as a covariate in the first model 
of the HMLR, as it significantly correlated with perception of risk for CVD. I entered all 
three independent variables as predictors of perception of risk for CVD on the second 
model of the HMLR. 
Results from the HMLR appear in Table 7. The first model of the HMLR, with 
take medication that could affect blood pressure entered as a predictor of perceived risk 
for CVD, was significant, F(1, 228) = 3.80, p = .046, R2 =.016. Based on the coding of 
the predictor variable, this finding indicated that taking medication that could affect 
blood pressure significantly aligned with higher perceived risk for CVD, β(230) = .140, 
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p = .046. The second model, in which the independent variables of highest level of 
education, years worked as a RN, and gender predicted perceived risk for CVD, was 
significant, Fchange (3, 225) = 2.85, p = .038, R2change = .036. However, only gender 
emerged as a significant predictor of perceived risk for CVD, β (230) = -.163, p = .015. 
Based on the coding of the gender variable, this significant result indicated that being 
male significantly aligned with increased perceived risk for CVD.1 The covariate of take 
medication that could affect blood pressure was no longer a significant predictor of 
perception of risk for CVD, β (230) =.122, p = .066 in the second model of the HMLR. 
Table 7 
Hierarchical Multiple Linear Regression (HMLR): Take Medication That Could Affect 
Blood Pressure (Covariate), Highest Level of Education, Years Worked as a Registered 
Nurse, and Gender Predicting Perceived Risk for Cardiovascular Disease (N = 230) 
  Model 1  Model 2 
  B SE B β  B SE B β 
Medication   1.42 .749 .140*  1.35 .731 .122 
Level of education      -.445 .310 -.094 
Years worked as an RN      .178 .147 .082 
Gender       -2.20 .895 -.163* 
R2 .016    .036    
F for R2 3.80    2.85    
p .046    .038    
Note. RN = registered nurse; *p < =.05 
Research Question 1. The first research question was, “Is there a significant 
association between nurses’ years of education and perceived risk for CVD?” Results 
                                                           
1 An independent samples t-test confirmed this finding. Male nurses had a significantly higher mean scores 
on the PRHDS (n = 37, M = 27.86, SD = 4.63) than did female nurses (n = 193, M = 26.00, SD = 4.99), 
t(228) = 2.11, p = .036 
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from the HMLR showed no significant associations between nurses’ years of education 
and perceived risk for CVD, β (230) = -.094, p = .153. Based on the nonsignificant 
findings, I retained the null hypothesis, “There is no association between nurses’ years of 
education and perceived risk for CVD.” 
Research Question 2. The second research question was, “Is there a significant 
association between nurses’ years of practice and perceived risk for CVD?” Results from 
the MLR showed that nurses’ years of practice was not significantly associated with 
perceived risk for CVD, β (230) = .082, p = .226. Due to the lack of significant findings, I 
retained the null hypothesis, “There is no association between nurses’ years of practice 
and perceived risk for CVD.” 
Research Question 3. The third research question was, “Is there a significant 
association between nurses’ gender and perceived risk for CVD?” Results from the MLR 
showed that gender did significantly align with perceived risk for CVD, β (230) = -.163, 
p = .015. Based on the coding of the gender variable, this significant result indicated that 
being male significantly aligned with increased perceived risk for CVD. The significant 
findings led to the rejection of the null hypothesis, “There is no association between 
nurses’ gender and perceived risk for CVD.” 
Multiple Linear Regression 2: Research Questions 4–6 
The fourth through sixth research questions examined if highest level of education, 
years worked as a RN and gender were significant predictors of knowledge of 
pharmacogenetic testing for CVD. As no demographic variables significantly correlated 
with the dependent variable of knowledge of pharmacogenetic testing for CVD, only one 
model was required for the regression analysis. The collective entry of the three 
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independent variables in one model as predictors of knowledge of pharmacogenetic 
testing for CVD required the use of an MLR. 
Results from the MLR appear in Table 8. The overall regression model was not 
significant, F (3, 226) = 1.94, p = .095, R2 =.024. When examining individual predictors, 
however, one variable, highest level of education, did significantly align with knowledge 
of pharmacogenetic testing for CVD, β (230) = .164, p = .042. As education level 
increased, so did knowledge of pharmacogenetic testing for CVD. 
Table 8 
Multiple Linear Regression: Highest Level of Education, Years Worked as a Registered 
Nurse, and Gender Predicting Knowledge of Pharmacogenetic Testing for 
Cardiovascular Disease (N = 230) 
  Model 1 
  B SE B Β 
Level of education  .043 .022 .164* 
Years worked as an RN  -.009 .006 -.103 
Gender   .024 .035 .046 
R2 .024    
F for R2 1.94    
p .095    
Note. RN = registered nurse; *p < =.05 
Research Question 4. The fourth research question was, “Is there a significant 
association between nurses’ years of education and knowledge of pharmacogenetic 
testing for CVD?” Results from the MLR showed significant associations between nurses’ 
years of education and knowledge of pharmacogenetic testing for CVD, β (230) = .164, 
p = .042. As years of education increased, so did knowledge of pharmacogenetic testing 
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for CVD. The significant findings led to the rejection of the null hypothesis, “There is no 
association between nurses’ years of education and knowledge of pharmacogenetic 
testing for CVD.” 
Research Question 5. The fifth research question was, “Is there a significant 
association between nurses’ years of practice and knowledge of pharmacogenetic testing 
for CVD?” Results from the MLR showed that nurses’ years of practice did not 
significantly align with knowledge of pharmacogenetic testing for CVD, β (230) = -.103, 
p = .126. Due to the lack of significant findings, I retained the null hypothesis, “There is 
no association between nurses’ years of practice and knowledge of pharmacogenetic 
testing for CVD.” 
Research Question 6. The sixth research question was, “Is there a significant 
association between nurses’ gender and knowledge of pharmacogenetic testing for CVD?” 
Results from the MLR showed that gender did not significantly align with perceived risk 
for CVD, β (230) = .046, p = .495. As I found no significant results, the null hypothesis, I 
retained “There is no association between nurses’ gender and knowledge of 
pharmacogenetic testing for CVD.” 
Hierarchical Linear Regression: Research Question 7 
The seventh and last research question examined whether a significant association 
existed between nurses’ perceived risk for CVD and their acceptance of pharmacogenetic 
testing for CVD. As knowledge of pharmacogenetic testing for CVD significantly aligned 
with acceptance of pharmacogenetic testing for CVD, I entered it as a covariate in the 
first model of the HLR. I entered the single predictor of perceived risk for CVD on the 
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second model of the HLR as a predictor of acceptance of pharmacogenetic testing for 
CVD. 
Results from the HLR appear in Table 9. The first regression model, with 
knowledge of pharmacogenetic testing for CVD predicting acceptance of 
pharmacogenetic testing for CVD, was significant, F(1, 228) = 3.86, p = .048, R2 = .017. 
As knowledge of pharmacogenetic testing for CVD increased, so did acceptance of 
pharmacogenetic testing, β (230) = .134, p = .048. The second model of the HLR, with 
perceived risk of CVD entered as a predictor of acceptance of pharmacogenetic testing, 
was not significant, F(1, 227) = 2.78, p = .097, R2 =.012. Knowledge of pharmacogenetic 
testing nonetheless remained a significant predictor of acceptance of pharmacogenetic 
testing, β (230) = .129, p = .049, in the second regression model. Based on the lack of 
significance between perceived risk for CVD and acceptance of pharmacogenetic testing, 
I retained the null hypothesis for Research Question 7. 
Summary 
I conducted this quantitative study, which used a correlational research design, 
with 230 RNs working in acute-care settings in hospitals throughout the State of Georgia. 
The sample of 230 nurse participants was 66.9% of the original group of 344 nurses who 
accessed the Survey Monkey link. A substantial number of nurses (n = 26) did not 
provide consent and an additional 34 nurses did not complete the study survey even after 
having provided consent and meeting study criteria. The sample of 230 was nonetheless 
robust to achieve power at .80. An equal number (n = 168) of nurses reported never 
having had estrogen-related diseases, disorders, or events and not currently taking any 
medication that could affect their blood pressure. 
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Table 9 
Hierarchical Linear Regression: Knowledge of Pharmacogenetic Testing for 
Cardiovascular Disease (Covariate) and Perceived Risk for Cardiovascular Disease 
Predicting Acceptance of Pharmacogenetic Testing for Cardiovascular Disease (N = 
230) 
  Model 1  Model 2 
  B SE B Β  B SE B Β 
Knowledge of 
pharmacogenetic 
testing for CVD 
 3.47 1.75 .134*   3.45 1.85 .129* 
Perceived risk for 
CVD 
     -.113 .068 -.109 
R2 .017    .012    
F for R2 3.86    2.78    
p .048    .097    
Note. CVD = cardiovascular disease; *p < =.05. 
The descriptive statistics on the study variables provided additional insights into 
the sample of nurses in this study. The mean score on the PRHDS scale was relatively 
low, indicating that, as a group, these nurses did not perceive themselves to be at risk for 
CVD. The score on the APS indicated that participants had neither high nor low levels of 
acceptance of pharmacogenetic testing for CVD. The participants had low levels of 
knowledge of pharmacogenetic testing for CVD, based on the mean PKS test score of 
68%. 
I conducted three types of linear regression models (HMLR, MLR, and HLR) for 
hypothesis testing, and a few findings were found to be significant. Male gender 
significantly aligned with increased perceived risk for CVD; that is, male nurses reported 
higher levels of perceived risk for CVD than did female nurses. Highest level of 
education emerged as significantly associated with increased knowledge of 
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pharmacogenetic testing: as education level increased, so did knowledge of 
pharmacogenetic testing. Other findings that emerged as significant included significant 
associations between taking medications that could affect blood pressure with increased 
perceived risk for CVD and knowledge and acceptance of pharmacogenetic testing for 
CVD. I discuss these findings in greater detail, especially in relation to previous research, 
in Chapter 5. 
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Chapter 5: Introduction 
The U.S. healthcare system has become a patient-centered medical community 
that is quickly adopting pharmacogenetic testing practices for CVD (ANA, 2015; Heller 
et al., 2014). The knowledge base of nurses has grown beyond basic CVD concepts, and 
nurses increasingly need to have knowledge of pharmacogenetic testing for CVD to best 
advocate for such testing and translate the meaning of such testing to their patients (ANA, 
2015). However, empirical evidence suggests that nurses have limited understanding of 
pharmacogenetic testing (Bannur et al., 2014; Roederer et al., 2012). This lack of 
knowledge coupled with nurses’ perceptions of being at low risk for CVD, despite having 
numerous CVD risk factors, may lead to resistance in advocating for the use of 
pharmacogenetic testing for CVD, which can ultimately impair patient health. 
This quantitative study, which had a response rate of 14.9%, was conducted with 
230 predominantly (83.9%) female RNs working in acute-care medical settings in the 
state of Georgia. The study was guided by Rosenstock’s (1978) HBM. In the first set of 
research questions, I examined, through HMLR, if the modifying factors of nurse gender, 
highest level of education, and years of experience significantly predicted nurses’ 
perceived risk for CVD, controlling for taking medication that could affect blood 
pressure. Only one independent variable, gender, was significant: men more than women 
perceived themselves to be at increased risk for CVD. The covariate of taking medication 
that could affect blood pressure also significantly predicted perceived risk for CVD. The 
second set of research questions examined, through MLR, if these same modifying 
factors significantly predicted nurses’ knowledge of pharmacogenetic testing for CVD. 
Highest level of education was the only significant predictor of knowledge of 
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pharmacogenetic testing for CVD; as education level increased, so did knowledge. The 
last research question, which I addressed through the use of an HLR, inquired as to 
whether perceived risk for CVD significantly aligned with acceptance of 
pharmacogenetic testing for CVD, controlling for knowledge of pharmacogenetic testing 
for CVD. Perceived risk for CVD was not a significant predictor of acceptance of 
pharmacogenetic testing for CVD (the covariate of knowledge of pharmacogenetic 
testing for CVD was significant). 
Interpretation of the Findings 
I had empirical and theoretical goals that I attempted to achieve with this 
quantitative study. My primary empirical goal was to enhance understanding of nurses’ 
perceived risk for CVD and if certain demographic modifying factors significantly 
contributed to these perceptions. Researchers documented that nurses have numerous 
health, mental health, and health-related behaviors and demographic risk factors for CVD 
(ANA, 2015; Baer et al., 2011; Fair et al., 2009; Louie & Wedell, 2014; Khan et al., 
2012) and yet, as a group, nurses do not perceive themselves to be at risk for developing 
CVD (Jones et al., 2006). An additional goal was to address gaps in the nursing literature 
concerning nurses’ knowledge and attitudes toward pharmacogenetic testing. 
Rosenstock’s (1974) HBM provided a theoretical framework from which to examine 
these constructs and relationships. This section of the chapter is devoted to an 
examination of the study findings. I discuss the results in relation to prior empirical work 
conducted on pertinent study constructs as well as the applicability of Rosenstock’s 
(1974) HBM. 
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Interpretation of Findings: Comparisons to Prior Research Findings 
The first goal of this study was to determine if the demographic modifying factors 
of gender, highest level of education, and years worked as an RN significantly predicted 
increased levels of perceived risk for CVD. Evidence from this study showed that male 
gender did significantly align with increased perceived risk for CVD among nurses (as 
was the covariate of taking medication for blood pressure). Although no studies have 
examined these associations with samples of healthcare providers, an extensive body of 
research has examined actual and perceived risk for CVD among diverse patient groups 
(Imes & Lewis, 2014). In their review of the literature on the contribution of 
demographic and health factors on patients’ perceived risk for CVD, Imes and Lewis 
(2014) reported equivocal findings across studies with regard to patient gender. The 
researchers posited that the inconsistencies in gender differences and perceived risk for 
CVD were a result of the diversity of study-participant samples, noting that gender results 
were likely obscured by other modifiable (e.g., education level, history of tobacco use, 
obesity/ overweight, cholesterolemia, diagnosis of Type 2 diabetes) and unmodifiable 
(e.g., age, ethnicity, genetic predisposition) risk factors for CVD. 
This study further examined nurses’ knowledge of pharmacogenetic testing and 
the influence of gender, education level, and years of experience on such knowledge. 
Results from this study showed that education level but not gender or years worked as a 
RN was significant predictors of knowledge of pharmacogenetic testing for CVD. Social 
science studies that examined healthcare practitioners’ perceptions of pharmacogenetic 
testing have tended to focus on physicians and pharmacists (Yáu, Husain, & Haque, 
2015), even while acknowledging that the successful implementation of pharmacogenetic 
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testing is the nurse’s attitudes toward it (Chadwell, 2013). To this end, researchers know 
little of the personal characteristics of nurses that significantly align with knowledge of 
pharmacogenetic testing for CVD. Researchers showed that few differences exist in the 
profession, as a substantial majority, 66% to 84% of physicians, pharmacists, and nurses, 
reported having low levels of pharmacogenetic testing knowledge (Dodson, 2011; 
Dodson & Van Riper, 2011). Roederer et al. (2012) examined pharmacogenetic testing 
knowledge and attitudes among pharmacists. Results from the Roederer et al. study 
showed that, similar to the results in this study, pharmacists with higher levels of 
education (i.e., doctorates) had higher levels of pharmacogenetic testing knowledge than 
did pharmacists with lower levels of education. 
An interesting finding in the Roederer et al. (2012) study was that pharmacists 
who matriculated within the prior 5 years and thus had fewer years of experience, had 
higher level of pharmacogenetic testing knowledge than did pharmacists who 
matriculated over 5 years prior and thus had more years of experience. Moreover, 
pharmacists who had matriculated more than 30 years prior had the lowest 
pharmacogenetic-testing-knowledge scores (Roederer et al., 2012). Although the results 
were not significant in this study with regard to years of experience, they did show a 
negative relationship between nurses’ years of experience and pharmacogenetic-testing 
knowledge, suggesting that a similar finding might arise among nurses. The Roederer et 
al. findings suggested that exposure to pharmacogenetic testing is more a function of the 
contemporary healthcare educational system and less a function of on-the-job exposure to 
pharmacogenetic testing. 
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The final research question of this study examined whether nurses’ perceived risk 
for CVD led to significant increases in acceptance of pharmacogenetic testing for CVD. 
Results were not significant. Empirical work on acceptance of pharmacogenetic testing 
has predominantly focused on the acceptance of pharmacogenetic testing among patients. 
The literature on patient factors has documented consistent linkages between the specific 
patient demographic factors of young-adult status (i.e., ages 18–34 years), Caucasian 
ethnicity, and higher levels of education, and increased levels of acceptance of 
pharmacogenetic testing for CVD (Chan & Perry, 2012; Haga, O’Daniel, Tindall, Lipkus 
et al., 2012; Haga, O’Daniel, Tindall, Mills et al., 2012). In contrast, highest level of 
education was not a significant predictor of acceptance of pharmacogenetic testing for 
CVD among nurses in this study. I could locate no studies that examined the relationship 
between perceived risk for CVD and acceptance of pharmacogenetic testing for CVD in 
patients or healthcare providers. 
Results from this study also provided descriptive information on current topics 
highly relevant to the nursing field. The mean score on the Bannur et al. (2014) PKS in 
this study was 68%. The percentage of participants who failed the PKS, 14%, was higher 
than the percentage of study participants who received a score of 100%: 9.6%. These 
findings suggested a poor understanding of pharmacogenetic testing among nurses in this 
study. Kadafour et al. (2009) and Van Riper et al. (2011) found similar results, 
documenting mean pharmacogenetic-testing-knowledge test scores of 40% and 60.3%, 
respectively, among nurses. 
Another finding was that nurses perceived themselves to be at low risk for CVD. 
Substantial evidence exists from a robust body of empirical literature that nurses have 
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numerous modifiable and unmodifiable risk factors for CVD (ANA, 2015; Baer et al., 
2011; Chan & Perry, 2012; DPE, 2012; Fair et al., 2009; Khan et al., 2012; Lang et al., 
2012; Li et al., 2006; Louie & Wedell, 2014; McElligott et al., 2009; Nahm et al., 2012; 
Puett et al., 2009; Slater et al., 2005). However, the strong empirical focus on actual CVD 
risk factors in nurses has not, surprisingly, prompted empirical work on nurses’ perceived 
risk for CVD. The only work to date that has focused on nurses’ perceptions of their risk 
for developing CVD has been the qualitative study by Jones et al. (2006), who 
documented perceived low risk of CVD in a sample of African American nurses, despite 
this group having numerous risk factors for CVD. The results from the Jones et al. study 
align with results from this study. 
Interpretation of Findings: Comparisons to Health-Belief Model Framework 
This study tested various pathways delineated among health-factor variables 
proposed by Rosenstock (1974) in the HBM. The first three research questions tested 
theoretical relationships between the modifying factors of gender, highest level of 
education, and years of practice and the perception of susceptibility factor of perceived 
risk for CVD. The only modifying factor found to be significant was gender, with male 
nurses perceiving themselves to be at greater risk for CVD than female nurses. The fourth 
through sixth research questions tested if the modifying factors of gender, highest level of 
education, and years of practice significantly predicted the perceived benefits versus 
barriers factor of knowledge of pharmacogenetic testing for CVD. Highest level of 
education emerged as the only significant predictor of increased knowledge for 
pharmacogenetic testing for CVD. The seventh and last research question examined the 
relationship between the perception of susceptibility factor of perceived risk for CVD and 
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the likelihood of action behavior of acceptance of pharmacogenetic testing for CVD. 
Results indicated that nurses’ perceptions of their CVD risk did not significantly affect 
their acceptance of pharmacogenetic testing for CVD. 
The overall study findings did not provide support for the HBM in the context of 
nurses’ perceptions of their risk for CVD, their knowledge of pharmacogenetic testing for 
CVD, or their acceptance of pharmacogenetic testing for CVD. One assumption of the 
HBM is that individuals have the capacity to change their health-related behaviors for 
health promotion and disease prevention (Rosenstock, 1974; Rosenstock et al., 1988, 
1994). In this study, this idea was taken a step further: I posited that nurses’ perceptions 
of their own risk for CVD would lead to an increased acceptance of pharmacogenetic 
testing for CVD, which would likely influence their own health behaviors as well as the 
health behaviors of their patients. Although not a focus of this study, I found that nurses’ 
knowledge of pharmacogenetic testing, considered to be a theoretical perception of 
benefits versus barriers of health behavior factor, did influence their likelihood of action 
to accept pharmacogenetic testing for CVD. Results from this study suggest that the 
personal health of nurses is not nearly as important as their knowledge of 
pharmacogenetic testing for CVD in influencing their acceptance of such practices. 
Limitations of the Study 
Objectivity is of the utmost importance in empirical research, and a certain degree 
of objectivity is not only necessary but required to reach sound study conclusions 
(Stangor, 2014). However, research conducted with human subjects, especially research 
using nonexperimental methods, often has methodological, design, and data limitations 
that can reduce study objectivity and quality (Stangor, 2014). Although the link to the 
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study survey was sent to 1,545 nurses, only 344 nurses responded to the survey. 
Moreover, I removed 114 of the 344 cases from the data set due to some participants not 
providing informed consent, others not meeting study criteria, and still others not 
completing the survey. Although the sample of 230 nurses was large enough to achieve 
the desired power, it was a concern that the response rate was only 14.9%. A large 
nonresponse bias may increase the likelihood of self-selection bias in that participants 
who responded to the survey may have differed in some ways from those who did not. 
For example, participants who completed the study survey may have had fewer risk 
factors for CVD and thus perceived themselves to be at less risk for CVD, or they may 
have had more knowledge of pharmacogenetic testing for CVD. Both nonresponse and 
self-selection bias make it difficult to generalize study findings to the population of RNs 
working in acute-care settings in Georgia. 
The large nonresponse rate may have resulted from another limitation of using a 
convenience sample of nurses. Convenience sampling increased the likelihood that 
participants in this study were not a representative sample of the population of RNs 
working in acute-care settings in Atlanta, Georgia, which limited the generalizability of 
study findings and the external validity of this study (Stangor, 2014). Another limitation 
of this study was the use of a quantitative cross-sectional research design, which 
precluded the ability to infer cause and effect (as suggested by Stangor, 2014). 
Although researcher objectivity is a desired goal, researchers are human and are 
not necessarily neutral or value free (Stangor, 2014). In parallel, a possibility exists that 
participants differ in their understanding and interpretation of survey questions, which 
may have influenced study data (aligned with Stangor, 2014). The low pharmacogenetic-
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testing-knowledge score and its alignment with results from prior studies suggests that 
study participants were being truthful about their knowledge. They may have been less 
truthful about their perceptions of CVD risk. The instrument measuring nurses’ 
perceptions of risk for CVD displayed poor inter-item reliability, necessitating that I use a 
shortened version of the instrument. 
Recommendations 
I hope this study acts as a catalyst to promote additional empirical work as it 
pertains to nurses’ CVD health and their knowledge and acceptance of pharmacogenetic 
testing for CVD as well as the applicability of Rosenstock’s (1974) HBM to these topics 
and relationships. This study adds to the small body of literature (e.g., Jones, 2006) that 
has documented that, despite having numerous risk factors for CVD, nurses do not 
perceive themselves to be at risk for CVD. Additional empirical work is needed to further 
validate these results, as are studies that compare nurses’ actual versus perceived risk for 
CVD. Results from this study combined with those found in the Roederer et al. (2012) 
study suggest that recent matriculation may play more of a role than does length of 
experience in influencing nurses’ knowledge of pharmacogenetic testing for CVD. 
Studies are needed that examine the linkages between nursing school curricula, required 
nursing courses, and exposure to and training in pharmacogenetic-testing procedures and 
nurses’ knowledge and acceptance of pharmacogenetic testing for CVD. In parallel, 
studies that assess improvements in nurses’ knowledge and acceptance of 
pharmacogenetic testing for CVD as a result of their participation in professional-
development opportunities on pharmacogenetic testing for CVD are needed. 
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This study operationally defined HBM theoretical constructs and examined 
theoretical pathways in very specific ways. Results from this study did not lend strong 
support for the HBM. It may be that this study examined two research topics—perceived 
risk for CVD among nurses versus nurses’ knowledge and acceptance of 
pharmacogenetic testing for CVD—that shared little theoretical overlap. However, both 
topics have been recognized as having empirical relevance. A need persists for studies 
that use the HBM theoretical pathway to provide a more cohesive and comprehensive 
picture of factors that influence and are influenced by nurses’ health factors as they 
pertain to CVD compared to those that concern nurses’ knowledge and acceptance of 
pharmacogenetic testing for CVD. 
Implications for Social Change 
The positive social change that can result from this study’s findings include a 
direct impact on nursing knowledge and training through the development of targeted 
educational materials for acute-care nurses (and ultimately, patients) about CVD risk 
factors and pharmacogenetic testing, on patient health outcomes, and on the 
empowerment of acute-care nurses to act as patient advocates. Developing a better 
understanding of demographic and CVD risk factors among acute-care nurses will allow 
for specific intervention and targeted educational programs in nursing schools and 
training programs in healthcare organizations. Moreover, results from this study may 
facilitate future research on how acute-care nurses’ perceptions of CVD risk factors and 
pharmacogenetic testing influence their patient-care practices and patient advocacy, 
including increasing patient awareness and knowledge of CVD risk factors and the 
benefits of pharmacogenetic testing. 
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Conclusion 
This quantitative study investigated if acute-care nurses’ gender, highest level of 
education, and years of nursing practice significantly influenced their perceived risk for 
CVD and their knowledge of pharmacogenetic testing for CVD, and whether significant 
associations exist between nurses’ risk for CVD and acceptance of pharmacogenetic 
testing for CVD. The data analysis revealed some significant association between the 
independent and dependent variables in the seven research questions. Male gender 
significantly aligned with increased perceived risk for CVD more than female nurses. 
Highest level of education significantly aligned with increased knowledge of 
pharmacogenetic testing: as education level increased, so did knowledge of 
pharmacogenetic testing. Significant associations emerged between taking medications 
that could affect blood pressure with increased perceived risk for CVD and knowledge. 
The field of pharmacogenetic testing has existed for over 60 years; however, the 
empirical body of CVD pharmacogenetic testing literature is only a decade old (Tonk, 
Gurwitz, Maitland-van der Zee, & Janssens, 2016). Pharmacogenetic-testing empirical 
literature is still in its infancy. Studies in clinical biochemistry, behavioral genetics, 
pharmaceutical chemistry, and molecular biology are continuing to greatly eclipse the 
body of social science literature, especially studies on healthcare practitioners’ 
knowledge, use, and attitudes toward pharmacogenetic testing. A dearth of literature 
persists on the CVD health of nurses as well as their knowledge and acceptance of 
pharmacogenetic testing for CVD. The crucial role that nurses’ play in their patients’ 
achievement of their heart health necessitates that further research be conducted on these 
topics. 
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